<SEC-DOCUMENT>0001493152-25-009737.txt : 20250310
<SEC-HEADER>0001493152-25-009737.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310172722
ACCESSION NUMBER:		0001493152-25-009737
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250304
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scienture Holdings, Inc.
		CENTRAL INDEX KEY:			0001382574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39199
		FILM NUMBER:		25725003

	BUSINESS ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558
		BUSINESS PHONE:		(800) 261 0281

	MAIL ADDRESS:	
		STREET 1:		2420 BRUNELLO TRACE
		CITY:			LUTZ
		STATE:			FL
		ZIP:			33558

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRxADE HEALTH, INC
		DATE OF NAME CHANGE:	20210602

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRXADE GROUP, INC.
		DATE OF NAME CHANGE:	20140207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCELLINK INTERNATIONAL INC.
		DATE OF NAME CHANGE:	20081230
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:MEDS="http://trxade.com/20250304">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_MEDS_trxade.com_20250304 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20250304_20250304 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001382574 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000004" name="dei:EntityCentralIndexKey">0001382574</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="meds-20250304.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-03-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-04</xbrli:startDate>
        <xbrli:endDate>2025-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; margin-top: 0pt; font-size: 1pt; margin-right: 0pt; margin-bottom: 0pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20250304__20250304_z8hsAG5f25oe"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 OR 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20250304__20250304_zQ5sYgmZGlBk"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 4, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20250304__20250304_z5QIlpKjQtPb"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000011" name="dei:EntityRegistrantName">SCIENTURE
HOLDINGS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250304__20250304_z0BOIuNJEJd6"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20250304__20250304_z6cR4fGwCqdi"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000013" name="dei:EntityFileNumber">001-39199</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20250304__20250304_z0vMNla7OJYf"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000014" name="dei:EntityTaxIdentificationNumber">46-3673928</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    No.)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20250304__20250304_zdFBIKcYqatc"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000015" name="dei:EntityAddressAddressLine1">6308
Benjamin Rd</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20250304__20250304_zkPPsNgFRoxd"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 708</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20250304__20250304_zz2AKoPaJ2dg"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000017" name="dei:EntityAddressCityOrTown">Tampa</ix:nonNumeric></span>,
<span id="xdx_90E_edei--EntityAddressStateOrProvince_c20250304__20250304_zbWtQvcBQ6P5"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250304__20250304_zM6EFVxrtMk2"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000019" name="dei:EntityAddressPostalZipCode">33634</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--CityAreaCode_c20250304__20250304_zWNcf4t055wg"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000020" name="dei:CityAreaCode">(866)</ix:nonNumeric></span>
<span id="xdx_90E_edei--LocalPhoneNumber_c20250304__20250304_zRSWouQMBYQ4"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000021" name="dei:LocalPhoneNumber">468-6535</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
Telephone Number)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
Name or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--WrittenCommunications_c20250304__20250304_zlQ5kKdjXymc"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20250304__20250304_zmuF1sT75QJf"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250304__20250304_zkNTgBOyVGO7"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250304__20250304_zeNRC6b8rmQl"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20250304__20250304_zjwOFv0W8cK"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000026" name="dei:Security12bTitle">Common stock, par value
    $0.00001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--TradingSymbol_c20250304__20250304_zPNatpPJB653"><ix:nonNumeric contextRef="AsOf2025-03-04" id="Fact000027" name="dei:TradingSymbol">SCNX</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--SecurityExchangeName_c20250304__20250304_zhrud3TKfys2"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(The
    Nasdaq Capital Market)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250304__20250304_z7oquph6Ruh9"><ix:nonNumeric contextRef="AsOf2025-03-04" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 4, 2025, Scienture Holdings, Inc., through its wholly-owned subsidiary Scienture, LLC (the &#8220;Company&#8221;), entered into
an Exclusive Commercial and Supply Agreement (the &#8220;Agreement&#8221;) with&#160;Summit Biosciences Inc., a wholly-owned subsidiary
of Kindeva Drug Delivery L.P. (&#8220;Kindeva&#8221;). Kindeva is a company engaged in the research, development, and manufacturing of
pharmaceutical products. Pursuant to the Agreement, Kindeva granted the Company an exclusive, non-transferrable, non-sublicensable right
and license to commercialize REZENOPY&#174; (Nalaxone HCI Nasal spray 10mg/0.11mL) (the &#8220;Product&#8221;) within the United States
and its territories. The Company intends to use the exclusive right and license to price, launch, promote, market, distribute, and educate
the public on the Product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
earlier terminated, the term of the Agreement will remain in effect for 10 years from the date of first commercial sale of the Product
in the United States and its territories to an unaffiliated third-party. The Agreement will automatically renew for successive 1-year
periods unless either party terminates the agreement in accordance with its terms. Either party may terminate the Agreement if (i) the
other party materially breaches the Agreement and has not cured such breach during a period of 90 days following notice of the breach,
(ii) the Product is withdrawn from the market as a result of any ruling or requirement by the United States Food and Drug Administration
(the &#8220;FDA&#8221;), a voluntary recall by the FDA is issued, or there are material safety concerns that could significantly impact
the commercial viability of the Product, or (iii) the Product is the subject of a mass tort liability action or is subject to material
health and public safety concerns. The Company may terminate the Agreement upon 120 days prior written notice if the Company determines
that the Product is compromised by an adverse and material change in the market or other adverse and material business conditions. The
Agreement is also terminable by either party upon the occurrence of certain bankruptcy related events pertaining to the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, the Company is exclusively responsible, at its expense, for the commercializing the Product in the United States and
its territories in a manner that maximizes the net sales of the Product. The Company has final and sole authority for the pricing of
the Product, but has agreed to not reduce the sale price of the Product for reasons other than the impact of market demand for the Product,
after taking into account all relevant factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, Kindeva will retain control of all activities associated with manufacturing the Product, and be responsible for any
non-clinical or clinical studies regard the Product. Kindeva will provide a copy of the New Drug Application for the Product (the &#8220;NDA&#8221;)
to the Company as well as all related information and data necessary for the Company to commercialize the Product. Once the NDA is transferred
to the Company, the Company will be responsible for maintaining the NDA and deal with any regulatory authorities regarding the advertising
and marketing of the Product as well as any adverse drug experience reports for the Product that the Company directly receives. The initial
supply price for the Product to the Company is $9.20 per unit. Kindeva may increase that price not more than once each calendar year
after the launch of the Product to account for any increased manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Agreement, the Company and Kindeva agreed to form a joint steering committee within 30 days to oversee and coordinate their respective
activities under the Agreement with respect to any additional regulatory or development requirements needed to obtain any regulatory
approvals needed for the Company to fulfill its commercialization responsibilities. The joint steering committee will be comprised of
four members, with 2 members to be appointed by each of the Company and Kindeva. The joint steering committee is responsible for establishing
timelines for the launch of the Product, overseeing the development and commercialization of the Product, providing strategic direction
and performance criteria, and resolving disputes that might arise under and in connection with the Agreement. The joint steering committee
will meet 4 times per year, unless the Company and Kindeva agree to a different schedule. The joint steering committee must act by unanimous
vote of the members present at a meeting, provided that at least 1 member from each of the Company and Kindeva must be present at such
meeting, or may otherwise act by a written consent signed by all members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
exchange for the exclusive rights to develop and commercialize the Products, the Company agreed to pay Kindeva certain milestone payments,
net sales share payments, and NDA cost reimbursements, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            one-time commercial milestone payment of between $2.5 million and $10 million based on the
                                            achievement of certain pre-defined annual net sales targets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milestone
                                            payments totaling $1 million, $200,000 of which was due upon executing the Agreement, $300,000
                                            of which is due within 3 months of executing the Agreement, $250,000 of which is due upon
                                            delivery of the initial commercial supply of the Product, and $250,000 of which is due 3
                                            months after receipt of such commercial supply;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit-sharing
                                            payments representing 10% of the net sales by the Company of the Product, which will be reduced
                                            to 8% of the net sales on the market entry of a third party generic ANDA for the Product;
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
                                            profit-sharing payments representing 5% of the net sales until the total cumulative payments
                                            equals Kindeva&#8217;s cost of developing and receiving NDA approval of the Product, which
                                            was $12.8 million as of the date of the Agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Agreement, the Company agreed to place minimum order quantities of the Product of 3 batches of 450,000 units per year beginning in
2027 or, alternatively, pay Kindeva $1.242 million per year unless the Company elects to terminate the Agreement pursuant to its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing summaries of the Agreement does not purport to be complete and is qualified in its entirety by reference to the definitive
Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K. The Agreement contains customary representations
and warranties that the Company and Kindeva made to, and solely for the benefit of, the other party thereto in the context of all of
the terms and conditions of the Agreement and in the context of the specific relationship between the parties. The provisions of the
Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the Company
and Kindeva or as stated therein and are not intended as a document for investors and the public to obtain factual information about
the current state of affairs of the parties to those documents and agreements. Rather, investors and the public should look to other
disclosures contained in the Company&#8217;s filings with the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2025, the Company issued a press release announcing the its intention to commercially launch the Product. The press release
is filed as Exhibit&#160;99.1 hereto and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporate press release shall not be deemed &#8220;filed&#8221; for any purpose, including for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise be subject to the liabilities of such Section 18. The
information in this Item 7.01, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities
Act or the Exchange Act regardless of any general incorporation language in such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. With the
exception of historical matters, the matters discussed in the press releases include forward-looking statements within the meaning of
applicable securities laws. Such forward-looking statements include, among others, statements regarding the Company&#8217;s projects,
potential financial performance, and growth opportunities. The words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221;
&#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;hopes,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; and similar expressions
are intended to identify certain of these forward-looking statements. These statements are based on the Company&#8217;s expectations
and involve risks, uncertainties and other important factors that could cause the actual results performance or achievements of the Company
(or entities in which the Company has interests), or industry results, to differ materially from future results, performance or achievements
expressed or implied by such forward-looking statements. Certain factors that could cause the Company&#8217;s actual future results to
differ materially from those discussed are noted in connection with such statements, but other unanticipated factors could arise. Certain
risks regarding the Company&#8217;s forward-looking statements are discussed in the Company&#8217;s filings with the Securities and Exchange
Commission (&#8220;SEC&#8221;). Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management&#8217;s
view only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions
or circumstances.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive Commercial and Supply Agreement dated March 4, 2025, by and between Scienture, LLC and Summit Biosciences Inc.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">99.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm">Press Release dated March 6, 2025</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded with the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Exhibits and Schedules have been omitted pursuant to Item&#160;601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit and schedule to the SEC upon request.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCIENTURE HOLDINGS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Surendra
    Ajjarapu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surendra Ajjarapu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 10, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLOr7GWPDhVxigwRX6vLpLg1I61TP8m/tG6IISSEe0+uEBOxoqVpkOE0Lws4YNs12iOUWCOjvWBw5OtNBmGXeDXOs7Z+OH9gToHBwKSxSs9BGKy9cVhlIGfTRE5VClJlYe63IvrqOdnaVGi90Q1oW8GeqWODXvNr/HDQT7LUvoaoI7IzZDNIYjnKb1AyUbCjXj+Ibw6KIhfRZKhIrJjuXXAtnh7tl4RFg22IcyP97+gDBU1Kig== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXCLUSIVE
COMMERCIAL and SUPPLY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Exclusive Commercial and Supply Agreement (hereinafter, this &ldquo;<B>Agreement</B>&rdquo;) is entered into by and between:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMIT
BIOSCIENCES INC.</B>, a Delaware corporation and wholly owned subsidiary of Kindeva Drug Delivery L.P., with corporate address at 1513
Bull Lea Rd., Lexington, KY 40511 (hereinafter referred to as &ldquo;<B>KNDD</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCIENTURE,
LLC (a wholly owned subsidiary of Scienture Holdings, Inc.)</B>, a company incorporated under the laws of the State of Delaware, with
corporate address at 20 Austin Blvd, Commack NY 11725, U.S.A., (hereinafter referred to as &ldquo;<B>SCNX</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
and SCNX may jointly be referred to as the &ldquo;<B>Parties</B>&rdquo; and individually each one as a &ldquo;<B>Party</B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            is a company engaged in the research, development, and manufacturing of pharmaceutical products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -34.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>II.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCNX
                                            is a company involved in the development and commercialization of branded pharmaceutical
                                            products; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -34.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCNX
                                            is interested in the Product and desires to obtain it from KNDD and KNDD desires to grant
                                            SCNX exclusive rights to Commercialize (as defined below) the Product in the Territory (as
                                            defined below), on the terms and conditions set forth in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -34.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE, </B>in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMS
AND CONDITIONS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following terms, when used in their capitalized form in the Agreement shall have the following
                                            meanings:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ADEs&rdquo;
has the meaning set forth in Section 5.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
shall mean, with respect to either Party hereto, any person, partnership, corporation, organization, or other entity that directly or
indirectly controls, or is directly or indirectly controlled by, or is under common control with such Party. A person or entity shall
be regarded as a controlling party, if (i) it owns more than 50% (fifty percent) of the voting stock or other ownership interest of such
other entity, or (ii) it directly or indirectly possesses sufficient authority to direct the adoption and/or execution of the policies,
management or operations of such party by any means whatsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the Preamble, and unless the context otherwise requires, includes the Recitals and Schedules, supplements
and any complementary or ancillary agreement signed by the Parties in accordance with the terms and conditions hereof</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Laws</B>&rdquo; means all laws, statutes, ordinances, codes, rules and regulations, as applicable, to which a Party is subject and which
are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to
the performance by the Parties of their respective obligations under this Agreement, including without limitation cGLP, cGCP and cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;c<B>GCP</B>&rdquo;
means current good clinical practice standards, practices and procedures, including for designing, conducting, performing, monitoring,
auditing, analyzing, recording and reporting trials that involve the participation of human subjects, promulgated, enforced, or endorsed
by the FDA as set forth in the FFDCA and the &ldquo;Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,&rdquo; and
related regulatory requirements imposed by any other Regulatory Authority in the Territory, as applicable, as such standards, practices
and procedures may be updated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>cGLP</B>&rdquo;
means current good laboratory practice standards, including for a quality system, standards, practices, and procedures concerned with
the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed,
monitored, recorded, reported and archived, promulgated, enforced, or endorsed by the FDA or any other Regulatory Authority applicable
to the Territory, including as defined in 21 C. F. R. Part 58 relating to quality, as such standards may be updated from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>cGMP</B>&rdquo;
means the current standards relating to current Good Manufacturing Practices, including for the quality oversight, design, Manufacturing,
Development, storing, repackaging, testing, packing, relabeling, commercial and clinical distribution, transportation, and handling,
for fine chemicals, Drug Substance, intermediates, bulk products, finished pharmaceutical products and associated delivery systems under
Applicable Law or as otherwise promulgated, enforced, or endorsed by the FDA or any other Regulatory Authority applicable to the Territory,
as amended from time to time, including those set forth in 21 U.S.C. &sect; 351(a)(2)(B), in FDA regulations at 21 C.F.R. Parts 210,
211.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Change
of Control</B>&rdquo; means, with respect to the Parties, a change in ownership or control of that Party effected through: (1) the acquisition,
directly or indirectly, by any entity or related group of entities, from existing shareholders of such Party of beneficial ownership
of securities possessing more than fifty percent (50%) of the total combined voting power of the Party&rsquo;s outstanding securities
that results in such entity or group of entities having effective control over the management and business affairs of such Party, or
(2) a merger or consolidation of such Party with another entity in which securities possessing more than fifty percent (50%) of the total
combined voting power of the Party&rsquo;s outstanding securities issued and existing as of just before such transaction are transferred
to an entity or entities different from the entities holding those securities immediately prior to such transaction, or (3) the sale,
transfer or other disposition of all or substantially all of the Party&rsquo;s business or assets to which this Agreement relates. A
transaction intended to operate as a change of management of the Party including a &ldquo;reverse merger&rdquo; shall be deemed a Change
of Control. A transaction primarily for financing purposes involving the issuance of newly issued securities by a Party in exchange for
cash (or other valuable consideration) paid to the Party shall not be a Change of Control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>CMC
Information</B>&rdquo; means Information related to the chemistry, manufacturing and controls of the Product, as specified by the FDA
and other applicable Regulatory Authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;CMO&rdquo;
</B>means a contract manufacturing organization which is compliant with cGMP practices and has successfully cleared an FDA inspection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Cost
of Goods Sold&rdquo; </B>or <B>&ldquo;(COGS)&rdquo; </B>shall mean the fully burdened costs in testing, manufacturing or acquiring the
Materials, the manufacturing, testing and analysis of the finished dosage of the Product, including in process testing, labeling, and
packaging, including Direct Labor and Benefits and Overhead, all determined in accordance with U.S. GAAP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Competing
Product&rdquo; </B>shall mean any pharmaceutical product containing the same Drug Substance in the same dose (10mg/0.11mL) as the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commercially
Reasonable Efforts</B>&rdquo; means the level of efforts and resources (including the promptness with which such efforts and resources
would be applied) consistent with the efforts and resources normally used by a similarly situated pharmaceutical or biotechnology company
in the exercise of its reasonable business discretion relating to the development or commercialization of a pharmaceutical product with
similar product characteristics that is of similar market potential at a similar stage of development or commercialization, taking into
account issues of efficacy, safety, patent and regulatory exclusivity, product profile, anticipated or approved labeling, present and
future market potential, competitive market conditions, the proprietary position of the compound or product, the regulatory structure
involved, and other technical, legal, scientific, medical or commercial factors, and the profitability of the product, including in light
of pricing and reimbursement issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commercialization</B>&rdquo;,
with a correlative meaning for &ldquo;<B>Commercialize</B>&rdquo; and &ldquo;<B>Commercializing</B>&rdquo;, means all activities undertaken
before and after obtaining Regulatory Approvals relating to the pre-launch, launch, promotion, detailing, medical education and medical
liaison activities, marketing, pricing, reimbursement, sale, and distribution of the Product, including strategic marketing, sales force
detailing, advertising, market and customer support, commercial distribution of the Product, and invoicing and sales activities. For
clarity, Commercialization shall not include any activities related to Developing or Manufacturing the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidential
Information</B>&rdquo; means the terms and conditions of this Agreement as well as all proprietary information delivered or disclosed
either orally or in written from, by or on behalf of the disclosing Party to the receiving Party that may be technical information, marketing,
business and financial information, scientific data, and all other information which a reasonable person would treat confidentially that
relates to the Product or the business of a Party. Confidential Information shall not include any information which the receiving Party
can show:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was
                                            known to or lawfully in the possession of the receiving Party prior to the date of its actual
                                            receipt from the disclosing party as demonstrated by competent written records;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            readily available to the public, other than through any act or omission of the receiving
                                            Party in contravention of this Agreement or any other agreement between the Parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was
                                            disclosed by a third party not under an obligation of confidentiality to the disclosing Party;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                            subsequently independently developed by the receiving Party without use of, reliance upon
                                            or reference to the disclosing Party&rsquo;s Confidential Information as demonstrated by
                                            competent written records.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -29.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -29.05pt"><IMG SRC="ex1-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -29.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Conforming
Product</B>&rdquo; has the meaning set forth in Section 9.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consequential
Damages</B>&rdquo; means any punitive, indirect, special or consequential damages, including, without limitation, loss of anticipated
profits, loss of profits, loss of time, loss of opportunity, loss of reputation or any other economic loss suffered or incurred as a
result of this Agreement whether such loss or damage may be based upon principles of contract, warranty, negligence or other tort, breach
of any statutory duty, the failure of any limited or exclusive remedy to achieve its essential purpose or otherwise, and whether or not
such damages were foreseeable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Control</B>&rdquo;
or &ldquo;<B>Controlled by</B>&rdquo; means, with respect to any material, Information, or intellectual property right, that a Party,
whether directly or indirectly (a) owns, or (b) has a license or sublicense (other than a license granted to such Party under this Agreement)
to such material, Information, or intellectual property right and, in each case, has the ability to grant to the other Party access,
a license, or a sublicense (as applicable), to the foregoing on the terms and conditions set forth in this Agreement without violating
the terms of any existing agreement or other arrangement with, or having to pay any amounts to, any Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Damages&rdquo;
</B>means any and all losses, liabilities, damages, costs and expenses paid or payable to a Third Party, including, without limitation,
those incurred in connection with a judgment or settlement. For the avoidance of doubt, a Party&rsquo;s attorney shall not be considered
a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Data</B>&rdquo;
means all data related to the Product, including CMC Information, non-clinical data, pre-clinical data and clinical data, generated by
or on behalf of a Party or its Affiliates or Subcontractors. For clarity, Data does not include any patentable Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Development</B>&rdquo;,
with a correlative meaning for &ldquo;<B>Develop</B>&rdquo; and &ldquo;<B>Developing</B>&rdquo;, means all activities reasonably necessary
for, or requested or required by a Regulatory Authority as a condition or in support of, maintaining the Regulatory Approval of the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Direct
Labor and Benefits</B>&rdquo; means that portion of basic wages, labor and related payroll taxes and employee benefits spent in production
and quality control of the Product, which are directly related to the Product and charged to the manufacturing and supply of the Product,
all determined in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Drug
Substance</B>&rdquo; means the active pharmaceutical ingredient Naloxone HCl.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
Date</B>&rdquo; shall mean the last of the dates appearing beside the signature of this Agreement by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration, or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Force
Majeure</B>&rdquo; means any case of an extraordinary circumstance beyond the reasonable control of a Party that prevents such Party
from performing the obligations assumed in this Agreement (except for a Party&rsquo;s payment obligations hereunder), such as a local
or national emergency being declared, acts of God (including, but not limited to, fire, floods, earthquakes, strikes and riots, epidemic,
pandemic, acts of terrorism, shortage of raw materials), as well as any other similar cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Indemnified
Party</B>&rdquo; has the meaning set forth in Section 12.3.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Indemnifying
Party</B>&rdquo; has the meaning set forth in Section 12.3.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Information</B>&rdquo;
means any data (including Data), results, technology, business, financial, technical, scientific, trade, research, manufacturing, marketing,
product, supplier and other information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets,
practices, techniques, methods, processes, inventions, developments, specifications, formulae, software, algorithms, marketing reports,
expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting
from non- clinical studies), CMC Information, stability data and other study data and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Intellectual
Property</B>&rdquo; means the Know-How, Patent Rights, Trademarks and any non-registered intellectual property contained in the NDA for
the Product, and any registered or non-registered intellectual property rights for the Drug Substance or the Product, in each case, to
the extent Controlled by KNDD or its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Invention</B>&rdquo;
means any inventions or discoveries, including Information, processes, methods, assays, designs, protocols, and formulas, and improvements
or modifications thereof, patentable or otherwise, that are generated, developed, conceived or reduced to practice by or on behalf of
a Party or its Affiliates, Subcontractors, licensees or sub-licencees in respect of the Product pursuant to activities conducted under
this Agreement, in each case including all right, title and interest in and to the intellectual property rights therein and thereto;
provided, however, that Inventions shall exclude Data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IP
Claims</B>&rdquo; has the meaning set forth in Section 11.4.1&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Joint
Steering Committee</B>&rdquo; or &ldquo;<B>JSC</B>&rdquo; shall have the meaning set forth in Article 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Know-How</B>&rdquo;
means any Information or material that is Controlled by KNDD at any time during the Term of this Agreement that is necessary or useful
to Commercialize the Product in the Territory including, without limitation, ideas, concepts, discoveries, inventions, developments,
improvements, trade secrets, designs, devices, equipment, biological material, process conditions, algorithms, notation systems, works
of authorship, computer programs, technologies, formulas, techniques, methods, procedures, assay systems, applications, data, documentation,
reports, chemical compounds, products and formulations, whether patentable or otherwise. Know-How shall also include non-confidential
information and material to the extent such information and material first lost its confidentiality by virtue of its disclosure in an
issued patent or published patent application, a filing with a Regulatory Authority or as part of a legal proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Launch</B>&rdquo;
or &ldquo;<B>Launching</B>&rdquo; or &ldquo;<B>Launch Date</B>&rdquo; means the first commercial sale in the Territory of the Product
by SCNX, or SCNX&rsquo;s Affiliate, as the case may be, to an unaffiliated Third Party customer, after receipt of final Regulatory Approval
from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Manufacture</B>&rdquo;,
with a correlative meaning for &ldquo;<B>Manufacturing</B>&rdquo;, means all activities related to the manufacturing of a pharmaceutical
product, or any ingredient thereof, including, but not limited to, test method development and stability testing, characterization, formulation,
process development, manufacturing for use in non-clinical or clinical studies, manufacturing scale-up, quality assurance/quality control
development, quality control testing (including in process release and stability testing), packaging, release of product or any component
or ingredient thereof, quality assurance activities related to manufacturing and release of the product, and regulatory activities related
to all of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Materials</B>&rdquo;
means all materials and pharmaceutical ingredients, including Drug Substance, required for the manufacturing, labeling and packaging
of the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>NDA</B>&rdquo;
means NDA N215487 and all supplements and amendments that may be filed with respect to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>NDA
Cost</B>&rdquo; has the meaning set forth in Section 6.1.1&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Net
Sales</B>&rdquo; means the total gross sales of the Product (number of units shipped times the invoice price per unit) by or on behalf
of SCNX or designee, as the entity responsible for Commercialization, or their respective Affiliates to Third Party customers, less the
following deductions as actually accrued and taken: (i) chargebacks granted or allowed in the ordinary course of business in connection
with the sale of the Product; (ii) sales and excise taxes, customs and any other similar non-income based taxes, all to the extent added
to the sale price and paid by the selling party and not invoiced to the purchaser or refundable in accordance with Applicable Law and
without reimbursement from any Third Party (but not including taxes assessed against the income derived from such sale); (iii) actual
freight, insurance, customs clearing and other transportation charges all related to the transportation and all in accordance with the
standard practices of SCNX for other pharmaceutical products to the extent added to the sale price and set forth separately as such in
the total amount invoiced and without reimbursement from any third party; (iv) solely as related to SCNX customers, amounts to be repaid
or credited by reason of rejections, defects, recalls or returns or because of retroactive price reductions, chargebacks, rebates, promotional
discounts, promotional allowances or commissions to unaffiliated Third Parties; and (v) administrative fees from customers or buyers
directly related to the Product, rebates or allowances actually granted or allowed to group purchasing organizations, managed health
care organizations and to governments, including their agencies, or to trade customers, in each case that are not Affiliates of SCNX.
Net Sales shall be determined in accordance with U.S. GAAP consistently applied in accordance with the standard practices of SCNX for
other pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NSS
Report&rdquo; has the meaning set forth in Section 6.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Overhead</B>&rdquo;
means all customary and usual operating expenses directly related to the Product incurred by and in support of the particular manufacturing
cost centers, purchasing department and quality assurance operations related to the Product (including labor, related payroll taxes and
employee benefits), depreciation, general taxes, rent, repairs and maintenance, supplies, utilities and factory administrative expense,
but only to the extent directly related and properly allocable to testing, manufacturing or acquiring the Materials, or the manufacturing,
testing and analysis of the finished dosage of the Product, including in process testing, labeling and packaging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Patents</B>&rdquo;
means all patents (including all reissues, extensions, substitutions, confirmations, re-registrations, re-examinations, invalidations,
supplementary protection certificates and patents of addition) and patent applications (including all provisional applications, continuations,
continuations-in-part and divisionals) and all foreign counterparts of the foregoing, or as applicable portions thereof or individual
claims therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Patent
Rights</B>&rdquo; means all Patents Controlled by KNDD at any time before, during or after the Term of this Agreement, that claim the
composition of matter or formulation of, or the method of making, using or delivering, the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Product</B>&rdquo;
means &ldquo;REZENOPY<SUP>&reg;</SUP>&rdquo; (Naloxone HCl Nasal spray 10mg/0.11mL), NDA N215487.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Quality
Agreement</B>&rdquo; has the meaning set forth in Sectio 8.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Recall</B>&rdquo;
means the retrieval of the Product which presents a risk to the health of consumers, and/or does not comply with it is considered to
be in non-compliance with Applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Regulatory
Approval</B>&rdquo; means, with respect to the Product, all approvals of the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory
Authorities necessary for the commercial sale of the Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Regulatory
Authority</B>&rdquo; means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies,
departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to
the Product in the Territory, including the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Regulatory
Materials</B>&rdquo; means regulatory applications (including Regulatory Approval applications), submissions, notifications, communications,
correspondence, registrations, Regulatory Approvals or other filings or documents made to or received from a Regulatory Authority in
order to Develop, Manufacture, market, sell or otherwise Commercialize the Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Supply
Price&rdquo; </B>has the meaning set forth in Section 6.3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Term&rdquo;
</B>has the meaning set forth in Section 15.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Sales,
Marketing and Distribution Expenses&rdquo; </B>means the direct and indirect costs incurred by SCNX to commercially sell and market the
product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Specifications</B>&rdquo;
means the specifications of Product, as applicable, as set forth in the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Territory</B>&rdquo;
means the United States of America, the District of Columbia, the Commonwealth of Puerto Rico, Guam, American Samoa, the U.S. Virgin
Islands and all territories and possessions of the United States of America (including military bases).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Third
Party</B>&rdquo; means any person or entity other than SCNX, KNDD or an Affiliate of either of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trademark</B>&rdquo;
means the distinctive trademark designated and Controlled by the parties or registered and licensed by the parties for the Commercialization
of the Product in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            this Agreement, unless the context otherwise requires, (a) capitalized terms denoting the
                                            singular may include the plural and vice versa, (b) words of any gender include each other
                                            gender, (c) words such as &ldquo;herein,&rdquo; &ldquo;hereof,&rdquo; and &ldquo;hereunder&rdquo;
                                            refer to this Agreement as a whole and not merely to the particular provision in which such
                                            words appear, (d) the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo;
                                            shall be deemed to be followed by the phrase &ldquo;but not limited to,&rdquo; &ldquo;without
                                            limitation,&rdquo; &ldquo;inter alia&rdquo; or words of similar import, and (e) the words
                                            &ldquo;will&rdquo; and &ldquo;shall&rdquo; have the same.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            this Agreement, reference to a specified article, section, paragraph or Schedule shall be
                                            construed as reference to that specified article, section, paragraph or Schedule of the Agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Schedules of this Agreement form part of the Agreement and shall have the same force and
                                            effect as if expressly set out in the body of the Agreement and any reference to this Agreement
                                            shall include the Schedules.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LICENSES</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            by KNDD</B>. KNDD hereby grants to SCNX, subject to the terms and conditions hereof: an exclusive,
                                            (even as to KNDD and its Affiliates) non-transferable (except pursuant to Section 20.1),
                                            non-sublicensable (except to an Affiliate of SCNX), right and license under Intellectual
                                            Property solely to permit SCNX to Commercialize the Product in the Territory. For the avoidance
                                            of doubt, all Data and Information generated by KNDD or its Subcontractors that are necessary
                                            or useful to Commercialize the Product are included in the Know-How being licensed to SCNX
                                            under this Section 2.1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sublicensing</B>.
                                            SCNX shall not be entitled to sublicense any rights granted under Section 2.1 to any Third
                                            Party. For clarity, SCNX shall not be prohibited from engaging contractors, including any
                                            sales forces and discrete support services, in connection with exercising SCNX&rsquo;s rights
                                            under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reservation
                                            of Rights</B>. Notwithstanding anything in this Agreement to the contrary, KNDD reserves,
                                            exclusively for itself and its Affiliates, all rights to (a) use the Intellectual Property
                                            to make, have made, or otherwise Manufacture the Product within or outside the Territory,
                                            (b) use the Intellectual Property to Commercialize the Product outside the Territory, and
                                            (c) to use the Intellectual Property to make, have made, use, have used, sell, have sold
                                            any other products which are not the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVELOPMENT &amp; COMMERCIALIZATION</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B>.
                                            Subject to the terms and conditions of this Agreement (including Section 3.3), KNDD shall
                                            control and be responsible for all activities, costs and expenses related to the Manufacture
                                            of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subcontractors</B>.
                                            KNDD shall have the right to engage its Affiliates or subcontractors to conduct any activities
                                            necessary for the performance of any of its obligations under this Agreement, including the
                                            conduct of non-clinical studies, clinical studies, CMC activities, and regulatory services
                                            for the Product in the Territory under this Agreement (each, a &ldquo;<B>Subcontractor</B>&rdquo;),
                                            provided that (a) such Subcontractors are bound by written obligations of confidentiality
                                            and non-use consistent with this Agreement; (b) any subcontract granted or entered into by
                                            KNDD as contemplated in this Section 3.2 of the exercise or performance of all or any portion
                                            of the rights or obligations that KNDD may have under this Agreement shall not relieve KNDD
                                            from any of its obligations under this Agreement; (c) any act or omission by a Subcontractor
                                            shall be deemed an act or omission of KNDD hereunder; and (d) KNDD shall be responsible for
                                            each of its Subcontractors complying with all obligations of KNDD under this Agreement (including
                                            without limitation all restrictions placed on KNDD herein). All Subcontractors used by KNDD
                                            for cGLP-related, cGCP-related and cGMP-related work shall be FDA approved and compliant
                                            with FDA standards in order to Manufacture the Product in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercialization
                                            by SCNX</B>. SCNX will be solely responsible for Commercialization of the Product in the
                                            Territory and all related costs and expenses thereof (including, but not limited to, making
                                            all selling and pricing decisions at SCNX&rsquo;s sole discretion) and shall use Commercially
                                            Reasonable Efforts to Commercialize the Product in the Territory in a manner to maximize
                                            the Net Sales of the Product. SCNX shall also be responsible for finalizing the Launch Date
                                            the Product in the Territory; provided, that SCNX shall consider in good faith KNDD&rsquo;S
                                            views and opinions regarding an appropriate Launch Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            shall have no involvement in the pricing of Product to SCNX&rsquo;s distributors or other
                                            customers; SCNX shall have final and sole authority over such pricing with a view of maximizing
                                            the Product sales. Subject to the foregoing, SCNX agrees that it shall not reduce the sale
                                            price of Product other than for reasons, at SCNX&rsquo;s discretion, reasonably demanded
                                            by the market for the Product, taking into account all relevant factors, including but not
                                            limited to impact on the Net Sales value of Product. For the sake of clarity, this means
                                            that SCNX will not reduce the price of Product solely to benefit sales of another SCNX product(s)
                                            or combine the Product with other SCNX product(s) in a manner which materially and disproportionately
                                            reduces the Net Sales value of Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            parties shall have a mutual good faith discussion on the need and timing of the commercial
                                            launch of an OTC (Over the Counter) version of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOINT STEERING COMMITTEE</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Formation</B>.
                                            Within thirty (30) days of the Effective Date, the Parties shall form a joint steering committee
                                            to oversee and coordinate the Parties&rsquo; activities under the Agreement with respect
                                            to any additional regulatory or Development requirements that might be necessary for obtaining
                                            Regulatory Approval in order for SCNX to Commercialize the Product in the Territory (the
                                            &ldquo;<B>Joint Steering Committee</B>&rdquo; or &ldquo;<B>JSC</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition</B>.
                                            The Joint Steering Committee shall be comprised of four (4) total members, with two (2) members
                                            to be appointed by each of KNDD and SCNX. Subject to the foregoing, a member of the Joint
                                            Steering Committee may be replaced at any time at the discretion of the Party that appointed
                                            such Joint Steering Committee member.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Responsibilities.
                                            </B>The Joint Steering Committee shall have the following responsibilities<B>:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish
                                            timelines for the Launch of the Product in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oversee
                                            the Development and Commercialization of the Product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            strategic direction and performance criteria; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resolve
                                            disputes that may arise among the Parties&rsquo; respective representatives related to the
                                            activities conducted under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties hereby agree that the JSC shall have no power to amend, modify or waive any of the terms or conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Decision
                                            Making</B>. At each Joint Steering Committee meeting, at least one member appointed by each
                                            of KNDD and SCNX must be present to constitute a quorum. The JSC shall attempt in good faith
                                            to make decisions by consensus of the members present at any meeting; provided that decisions
                                            shall be made by unanimous vote, with all the members representing KNDD collectively having
                                            one (1) vote and all the members representing SCNX collectively having one (1) vote. The
                                            Parties shall cause their respective appointees to the JSC to comply with this Section 4.4
                                            and perform the activities for which the JSC is responsible under this Agreement. In all
                                            discussions and determinations of the JSC, the members of the JSC shall endeavor in good
                                            faith to act in the best commercial interest of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joint
                                            Steering Committee Dispute Resolution</B>. If the Parties&rsquo; representatives on the JSC,
                                            after reasonable discussion and good faith consideration of each Party&rsquo;s opinions,
                                            cannot reach agreement on a matter within the JSC&rsquo;s authority within fifteen (15) days
                                            after the JSC has met and attempted to agree on such matter (or such other period as the
                                            Parties may agree upon in writing), then such disagreement shall be referred to the President
                                            and Chief Executive Officers of each of SCNX and KNDD (or their respective designees) (collectively,
                                            the &ldquo;<B>Executive Officers</B>&rdquo;) for resolution. Any final decision that the
                                            Executive Officers mutually agree to in writing shall be conclusive and binding on the Parties.
                                            If the Executive Officers cannot reach agreement on a matter within thirty (30) days after
                                            such matter has been referred to them by the JSC (or such other period as the Executive Officers
                                            may agree upon in writing), then (a) KNDD shall have the tie-breaking vote, and the decision
                                            of KNDD&rsquo;s Executive Officer shall be final and binding on the JSC and the Parties,
                                            to the extent the matter primarily relates to the Manufacture of the Product, and (b) SCNX
                                            shall have the tie-breaking vote, and the decision of SCNX&rsquo;s Executive Officer shall
                                            be final and binding on the JSC and the Parties, to the extent the matter primarily relates
                                            to the Commercialization of the Product in the Territory. If the Executive Officers cannot
                                            reach agreement on any other matter (i.e., not subject to the foregoing sentence) within
                                            thirty (30) days after such matter has been referred to them by the JSC (or such other period
                                            as the Executive Officers may agree upon in writing), or if they in good faith cannot agree
                                            on whether a matter is subject to the final decision-making of authority of either Party,
                                            then the Parties shall invoke the dispute resolution procedure in accordance with Article
                                            18 hereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings</B>.
                                            The Joint Steering Committee shall meet four (4) times each calendar year unless the Parties
                                            mutually agree that the JSC shall meet more or less frequently. Participation in any meeting
                                            of the Joint Steering Committee may be in person, by telephone, by video conference or by
                                            other means of telecommunication that enables all members of the Joint Steering Committee
                                            participating in the meeting to communicate simultaneously with each other. A member of the
                                            Joint Steering Committee may, by written notice to each of the other members of the Joint
                                            Steering Committee, designate a proxy with voting authority (subject to Section 4.3) to attend
                                            such meeting in such member&rsquo;s place. In addition, the Joint Steering Committee may
                                            act without a formal meeting by a written consent signed, in one (1) original or multiple
                                            counterparts, by all the members of the Joint Steering Committee. Representatives of either
                                            Party, in addition to the members of the Joint Steering Committee, may attend Joint Steering
                                            Committee meetings as nonvoting observers at the invitation of either Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.7</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minutes</B>.
                                            The Joint Steering Committee shall keep accurate minutes of its meetings and record all decisions
                                            and all actions recommended or taken. Draft minutes shall be delivered to the members of
                                            the Joint Steering Committee within ten (10) calendar days after each meeting. The members
                                            of the JSC shall elect or appoint a secretary for each meeting and such secretary shall be
                                            responsible for the preparation and circulation of the draft minutes. Draft minutes shall
                                            be edited by the members of the Joint Steering Committee and shall be issued in final form
                                            only with their approval and agreement as evidenced by their signatures on the minutes. Minutes
                                            of the Joint Steering Committee meetings shall be deemed Confidential Information of each
                                            Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGULATORY MATTERS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
                                            Information Sharing and NDA Transfer</B>. KNDD shall keep SCNX reasonably informed, through
                                            meetings of the JSC of regulatory developments related to the Product in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            shall (a) after the Effective Date pursuant to a mutually agreed timeline provide SCNX with
                                            one (1) electronic copy of the NDA, Data and all other Information in KNDD&rsquo;s possession
                                            or Control that are reasonably necessary for SCNX to Commercialize the Product in the Territory
                                            and comply with all Applicable Laws in connection therewith. Any Data or Information (including
                                            CMC Information) provided under this Section 5.1.1 shall be treated and maintained by SCNX
                                            as the Confidential Information of KNDD. KNDD shall cooperate to effect the successful transfer
                                            from KNDD to SCNX of the NDA and each Party shall promptly submit any and all notices and
                                            authorizations to the FDA that are necessary to effect the transfer to and acceptance by
                                            SCNX of the NDA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition to the foregoing, KNDD shall promptly provide SCNX with copies of any Regulatory
                                            Materials received by KNDD or its Affiliates relating to the Commercialization of the Product
                                            in the Territory and shall keep SCNX reasonably informed of any material verbal communication
                                            or question relating to the Product received by KNDD or its Affiliates and Subcontractors,
                                            from any Regulatory Authority in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meetings
                                            with Regulatory Authorities</B>. At each regularly scheduled JSC meeting, the parties will
                                            provide each other a list and schedule of any in-person meeting or teleconference with Regulatory
                                            Authorities (or related advisory committees) in the Territory planned for the next calendar
                                            quarter that relates to the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NDA
                                            Maintenance: Once the NDA is transferred to SCNX, SCNX shall have responsibility to maintain
                                            such NDA with the appropriate Regulatory Authority in the Territory. SCNX shall be responsible
                                            for all the dealings with Regulatory Authorities on advertising and marketing matters. SCNX
                                            shall file any and all reports required for the Product by Regulatory Authorities in the
                                            Territory. SCNX shall be responsible for any submissions, fees, holding fees, or any other
                                            fees associated with the maintenance of the NDA, including the prescription drug user fee
                                            (PDUFA).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adverse
                                            Drug Experience Reports</U>. SCNX shall be responsible for filing with the Regulatory Authorities
                                            any Adverse Drug Experience reports (&ldquo;<B>ADEs</B>&rdquo;) for Product which it receives
                                            directly from Third Parties or from KNDD. ADEs shall be categorized and submitted by SCNX
                                            in accordance with Applicable Laws and guidance documents as published by the Regulatory
                                            Authorities</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL TERMS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNDD
                                            Development Milestone Payments and Net Sales Share</B>. In consideration for the rights granted
                                            under Section 2.1 of this Agreement, SCNX shall pay to KNDD milestone payments, Net Sales
                                            share payments and NDA Cost Reimbursement as listed in <U>Schedule A</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            accordance with Schedule A.c. SCNX shall pay KNDD its cost of developing the Product and
                                            receiving NDA approval for the Product (&ldquo;NDA Cost&rdquo;). As of the Effective Date,
                                            such NDA Cost totals twelve million eight hundred thousand dollars ($12,800,000), is summarized
                                            in Schedule B, and is subject to change if KNDD is required to make further investments towards
                                            the NDA prior to the transfer to SCNX. KNDD shall notify SCNX of any such changes to the
                                            NDA Cost.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the Term, SCNX shall, within thirty (30) days after the end of each calendar quarter, provide
                                            to KNDD a Net Sales share report for such calendar quarter (&ldquo;NSS Report&rdquo;). SCNX
                                            shall pay KNDD&rsquo;s share of the Net Sales amount generated during a calendar quarter
                                            within forty-five (45) days of the end of such calendar quarter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNDD
                                            One Time Commercial Milestone Payments</B>. In consideration for the rights granted under
                                            Section 2.1 of this Agreement, SCNX shall pay KNDD the One Time Commercial Milestone Payments
                                            sharing as listed in <U>Schedule A</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supply
                                            Price</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            initial supply price for the Product shall be nine dollars and twenty cents ($9.20) per unit
                                            (&ldquo;<B>Supply Price</B>&rdquo;). This initial estimated price is based on Ex Works shipping
                                            terms (Incoterms 2010) from KNDD&rsquo;s manufacturing facility in Lexington, Kentucky.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            more than once in each calendar year after launch, KNDD shall be entitled to increase the
                                            Supply Price for any increase in KNDD manufacturing cost, subject to KNDD notifying SCNX
                                            of any price increase no later than sixty (60) days prior to the effective date of such price
                                            increase, which for the avoidance of doubt, may not be applied to orders received prior to
                                            expiration of such sixty (60) day period. Any price increase to the Supply Price must be
                                            made solely to account for any increase in KNDD manufacturing cost and be based on the PPI
                                            Index.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><IMG SRC="ex1-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Extraordinary
                                            Costs and Price Increases</B>. Notwithstanding Section 6.3.2 above, KNDD shall provide to
                                            SCNX detailed documentation of, and may, charge SCNX directly at the time KNDD incurs, any
                                            extraordinary costs or price increases related to any of the following items:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            in the cost of raw materials, provided by KNDD, including but not limited to the components
                                            procured by KNDD, and general energy costs that are not within KNDD&rsquo;s reasonable control;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price
                                            increases due to taxes/assessments imposed by any authority or passed on to KNDD by its suppliers
                                            in the form of cost increases or in any other manner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            increased costs of manufacture or testing that SCNX or a Regulatory Authority may require
                                            be conducted and KNDD has agreed to conduct;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            costs incurred by KNDD in connection with any changes or modifications to the Specifications
                                            for Product made by or at the requested of SCNX and/or a Regulatory Authority; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            increased costs of manufacture resulting from a material reduction in volume.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.75in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
price increase/decrease is considered extraordinary under the present Agreement if it increases the then-current manufacturing costs
by more of five percent (5%). For the avoidance of doubt, KNDD may charge SCNX any costs incurred by KNDD required to implement activities
relating to items 6.3.3(iii) and (iv), in addition to any extraordinary price increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
                                            Terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Currency</B>.
                                            Any and all payments arising out from this Agreement shall be paid in United States Dollars.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invoices</B>.
                                            All undisputed amounts shall be due and payable under this Agreement within 30 days, of an
                                            invoice therefor from the other Party (including any milestones payable to KNDD as further
                                            detailed on <U>Schedule A)</U>. All invoices shall be delivered via e-mail and reflect the
                                            banking instructions for payment (i.e. name of the bank, the account number and any other
                                            relevant information for payment).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amounts set forth herein are exclusive of all applicable stamp, value-added, goods and services,
                                            excise, transfer, sales, use, property, gross receipts tax, or any similar tax imposed, assessed
                                            or collected by any tax authority, that KNDD is required to collect from SNCX (collectively,
                                            &ldquo;<B>Covered Taxes</B>&rdquo;). To the extent SNCX furnishes a valid and properly completed
                                            exemption certificate or other proof of exemption with respect to the Covered Taxes in a
                                            form reasonably satisfactory to KNDD, KNDD shall not collect such Covered Tax; provided that
                                            SNCX shall be responsible for such Covered Tax if such exemption certificate or other proof
                                            of exemption is disallowed by the applicable tax authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            for any Covered Taxes pursuant to Section 6.5.1 above, the Parties shall make all payments
                                            pursuant to this Agreement to one another free and clear of any deduction or withholding
                                            for taxes except to the extent a SNCX is required to deduct or withhold taxes by applicable
                                            law. To the extent a SNCX is required to deduct or withhold tax (other than any Covered Tax)
                                            in connection with a payment to any other party pursuant to this Agreement, then such SNCX
                                            shall timely pay over such deducted and withheld amounts to the applicable tax authority
                                            and promptly provide such other party with evidence of such payment. Where a relief, waiver
                                            or reduction of any deduction or withholding is available under applicable Law, the Parties
                                            shall cooperate to obtain such tax exemption from the relevant tax authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties shall cooperate and use commercially reasonable efforts to (i) minimize the amount
                                            of Covered Taxes under Section 6.5.1 above or any taxes required to be deducted and withheld
                                            under applicable law under Section 6.5.2 above, and (ii) claim the benefit of any exemptions
                                            or reductions in applicable tax rates, to the extent allowable under applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the avoidance of doubt, each Party shall be solely responsible for any taxes measure by or
                                            imposed on such Party&rsquo;s income.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Audit
                                            Rights.</U> During the Term and any applicable period thereafter, SCNX will keep accurate
                                            books and records for purposes of documenting the amount of the Net Sales and returns for
                                            the Product. Said books and records will be made available at SCNX&rsquo;s principal place
                                            of business. Upon at least forty-five (45) days prior written notice to SCNX, KNDD will have
                                            the right to have KNDD&rsquo;s independent public accountants (which accountants shall be
                                            reasonably acceptable to SCNX) obtain access to such books and records during reasonable
                                            business hours for the purpose of verifying, at KNDD&rsquo;s expense, the amount of the Net
                                            Sales, the calculation of the Net Sales share, and any other information reasonably necessary
                                            to verify the above calculations and information; provided, however, that this right may
                                            not be exercised more than once in any calendar year and no period of time may be audited
                                            more than once during the Term. KNDD will solicit or receive from such accountants only information
                                            relating to the accuracy of such calculations, and will only have access to information for
                                            the most recent one (1) calendar year. However, if in subsequent audits conducted in accordance
                                            with the requirements of this Section 6.6, it is discovered that an error occurred that might
                                            have carried back to previous years, SCNX shall provide the information for all previous
                                            contract years for purposes of identifying if the error carried back and correcting such
                                            error if necessary. SCNX will be entitled to require such accountants to sign a confidentiality
                                            agreement in form and substance reasonably satisfactory to SCNX, KNDD and such accountant.
                                            KNDD and SCNX will each receive the same report of the audit from such accountants which
                                            will contain their opinion of whether SCNX reports, calculations and payments have been accurate
                                            or not and, if not, by how much and for how long and how they arrived at their conclusions.
                                            The Parties may make inquiries of such accountants to clarify the contents of the report
                                            and the accountant&rsquo;s response will be provided to both Parties. If there is an underpayment
                                            of the Net Sales share to KNDD, KNDD will send an invoice to SCNX for the amount of the underpayment.
                                            Such invoice will be paid by SCNX within thirty (30) days after its receipt of such invoice.
                                            In the event any such audit reveals a shortfall in amounts paid to KNDD of five percent (5.0%)
                                            or more for the audited calendar year, then the reasonable costs and expenses of the audit
                                            including the fees and expenses of such accountants will be reimbursed to KNDD by SCNX. In
                                            the event any such audit report reveals an overpayment of the Net Sales share to KNDD during
                                            the audited calendar year, SCNX will send an invoice to KNDD for the amount of such overpayment.
                                            KNDD will pay such invoice within thirty (30) days after its receipt of such invoice. All
                                            information contained in reports issued by KNDD&rsquo;s independent public accountants pursuant
                                            to this Section 6.5 and all responses provided by such accountants in connection with related
                                            inquiries shall all be deemed Confidential Information of SCNX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE ORDERS, FORECASTS, MANUFACTURING AND PACKAGING ACTIVITIES</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supply
                                            of Products</B>. During the Term of this Agreement, SCNX shall purchase and KNDD shall supply
                                            commercial quantities of the Product for the Territory at a Supply Price of $9.20 per unit.
                                            During the Term, where possible, SCNX shall be named as an additional party to any supply
                                            agreement or contract KNDD executes with any CMO for supply of the Product in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchase
                                            Orders</B>. During the Term and in accordance with the terms herein, KNDD agrees to supply
                                            SCNX with Product pursuant to purchase orders delivered by SCNX from time to time in accordance
                                            with the terms of this Agreement. The amount of Product set forth in a purchase order will
                                            be based upon and consistent with the forecasts delivered by SCNX to KNDD pursuant to Section
                                            7.3 below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCNX
                                            Forecasts; Commercial Lead Times</B>. On or about five (5) months prior to the Launch Date,
                                            SCNX will provide KNDD with an initial forecast of its estimated orders for delivery of Product
                                            for the first twelve (12) months after first commercial sale of such Product in the Territory.
                                            By the end of each calendar quarter thereafter, SCNX will provide KNDD with an updated forecast
                                            for each of the following twenty-four (24) months. KNDD shall confirm to SCNX within twenty
                                            (20) days of its receipt of each such forecast that KNDD has the capacity to provide the
                                            quantities of a Product set out in that forecast. The forecasted amounts for the first six
                                            (6) months of each forecast shall be binding and shall be confirmed by a purchase order from
                                            SCNX. The remaining nine (9) months of each forecast constitute nonbinding, good faith estimates
                                            provided solely to assist KNDD in production planning, and the forecast for any period may
                                            be revised by SCNX by written notice to KNDD. Purchase orders shall be submitted one hundred
                                            (100) days before the specified delivery date. The Parties shall use Commercially Reasonable
                                            Efforts to supply the Product ordered pursuant thereto by the delivery dates specified on
                                            the applicable purchase orders. Without the Parties&rsquo; prior written agreement, no rolling
                                            forecast will vary the amounts of Product set forth in the previous rolling forecast for
                                            the same calendar month by more than twenty percent (20%). KNDD shall use Commercially Reasonable
                                            Efforts to supply quantities of a Product in excess of one hundred twenty-five percent (125%)
                                            of the most recent forecasted amount for the applicable period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.4</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNDD
                                            Specific Duties</B>. In addition to its general obligations relating to the supply of commercial
                                            quantities of the Products, KNDD shall perform the following services at KNDD&rsquo;s cost:
                                            (a) acquiring any and all raw materials, including Drug Substance, required to manufacture
                                            the Product, excipients and packaging components as necessary, subject to the terms of this
                                            Agreement and the Specifications; (b) maintaining and conducting quality control and testing
                                            of the Product in order to monitor compliance with all applicable standards and specifications
                                            required by the Specifications, the Product warranties pursuant to Section 10.2.7, and the
                                            Regulatory Approval; and (c) performing such other reasonable services as mutually agreed
                                            upon in writing by the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inability
                                            to Supply. During any period in which KNDD for any reason other than Force Majeure, fails
                                            to ship at least seventy five percent (75%) of the quantities of the Product set forth in
                                            a purchase order by the agreed to delivery date more than two times in a calendar year and
                                            SCNX would be in an out-of- stock situation, after a sixty (60) day cure period, it shall
                                            be responsible for any Third Party direct Damages arising from this situation, with such
                                            Damages not to exceed the amounts paid for the purchase orders in question. For the avoidance
                                            of doubt, SCNX shall be required to maintain a two (2) month supply of the Product as safety
                                            stock based on its then-current forecast.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            Product shall be shipped Ex-Works (INCOTERMS 2010) from KNDD&rsquo;s manufacturing facility
                                            in Lexington, Kentucky. Upon Product being made available for pick-up per this Section 7.6,
                                            KNDD shall issue an invoice to SCNX for the applicable Supply Price for all Product. The
                                            invoice shall contain a reference identifying the SCNX purchase order number.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRODUCT QUALITY AND MANUFACTURING PROCESSES; PACKAGING</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quality</B>.
                                            All Products sold by KNDD to SCNX under this Agreement will be subject to Product release
                                            and annual stability testing by KNDD to meet the Product Specifications and each of the test
                                            methods as well as the quality assurance standards established in the Specifications, the
                                            Product warranties pursuant to Section 10.2.7 and shall be tested by KNDD in accordance with
                                            the test methods set forth in the Specifications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Packaging</B>.
                                            KNDD shall supply each Product to SCNX packaged in accordance with the Specifications, the
                                            Product warranties pursuant to Section 10.2.7, Quality Agreement, Applicable Law and regulations,
                                            including, but not limited to, cGMP. In addition, KNDD will supply Product in bulk to SCNX
                                            to package in Unit Dose Cups at SCNX (or its CMO)&rsquo;s facility.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety
                                            Data Exchange and Quality Agreements</B>. Prior to the first commercial sale of the Product
                                            in the Territory, the Parties shall enter into mutually agreeable &ldquo;Safety Data Exchange
                                            Agreement&rdquo; for the Product. Additionally, KNDD and SCNX shall, and shall cause its
                                            contractors to, comply with the terms of the quality requirements set forth in a separate
                                            Quality Agreement for the Product, to be negotiated in good faith by the Parties and entered
                                            into by the Parties as soon as practicable after the date hereof and prior to first commercial
                                            sale of the Product in the Territory (the &ldquo;<B>Quality Agreement</B>&rdquo;). Such Quality
                                            Agreement will be incorporated herein by reference following execution by both Parties. Any
                                            amendments or revisions to the Quality Agreement must be approved by both Parties in writing.
                                            To the extent that any inconsistencies or conflicts exist between the Quality Agreement and
                                            this Agreement, the provisions in the Quality Agreement shall prevail with respect to quality
                                            related issues, and this Agreement shall prevail with respect to all other issues.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPECTION AND ANALYSIS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspection
                                            by KNDD</B>. Prior to shipment, KNDD shall analyze each lot of the Product being shipped
                                            in accordance with the test methods for compliance with the Specifications and the Product
                                            warranties pursuant to Section 10.2.7 subject to the Quality Agreement. KNDD will send to
                                            SCNX an electronic version of the original signed and dated certificate of analysis and certificate
                                            of release (with original copies to promptly follow by mail) prior to, or together with,
                                            each shipment of the Product, and will send a copy thereof to SCNX by electronic means prior
                                            to or at the time of each shipment. The certificate of analysis shall include the actual
                                            results of the testing of each Product being shipped. KNDD agrees to retain all records and
                                            documents necessary to fulfill the requirements established by the Regulatory Authority in
                                            the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspection
                                            by SCNX.</B> SCNX or its authorized representative will inspect all shipments of each Product
                                            upon its receipt and will promptly report any obvious physical defects in a Product to KNDD.
                                            SCNX shall test each Product for conformance to the results in the certificate of analysis
                                            in accordance with the test methods within ten (10) days of its receipt of the applicable
                                            Product and related records. Any defects which are not obvious physical defects or are outside
                                            the scope of testing of a Product as per the certificate of analysis (latent defects), will
                                            be reported to KNDD by SCNX within ten (10) days of SCNX&rsquo;s discovery of the same. If
                                            it is determined that the latent defect is caused by SCNX&rsquo;s improper handling or storage
                                            of a Product, KNDD shall not be held responsible.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Conforming
                                            Product.</B> Subject to the provisions of Section 9.4, if a Product does not meet the requirements
                                            of the Specifications, the Product warranties pursuant to Section 10.2.7 and/or the Regulatory
                                            Approval, then KNDD shall, within forty-five (45) days of delivery of the demand notice or
                                            the completion of the independent testing process, replace said Product with new Product
                                            that meets the requirements of this Agreement (the &ldquo;<B>Conforming Product</B>&rdquo;)
                                            at no additional charge to SCNX. KNDD shall reimburse SCNX for all reasonable out-of-pocket
                                            costs incurred by SCNX in properly disposing of such non-conforming Product. The demand notice
                                            given hereunder shall specify in reasonable detail the manner in which a Product fails to
                                            conform to the purchase order or otherwise fails to meet the requirements of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent
                                            Testing.</B> If SCNX notifies KNDD that a Product does not meet the requirements of the Specifications,
                                            the Product warranties pursuant to Section 10.2.7 and/or the Regulatory Approval, and KNDD
                                            does not agree with SCNX&rsquo;s position, KNDD will notify SCNX in writing within forty-
                                            five (45) days after its receipt of SCNX&rsquo;s demand of the reason for its disagreement
                                            and SCNX and KNDD will in good faith attempt to reach a mutually acceptable resolution of
                                            the dispute. If the Parties are unable to resolve the dispute after a reasonable period of
                                            time (such period not to exceed forty-five (45) days from the date of original demand notification),
                                            the matter will be submitted to an independent testing laboratory reasonably acceptable to
                                            SCNX and KNDD (which independent testing laboratory shall not be compensated on a contingency
                                            basis). SCNX and KNDD shall, in good faith, select such independent testing laboratory as
                                            soon as reasonably practicable. SCNX and KNDD will accept the judgment of the independent
                                            laboratory as final. The cost of such testing will be borne by the Party whose position is
                                            determined by the independent laboratory to have been in error.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recall.
                                            If any Regulatory Authority in the Territory issues or requests a Recall, market withdrawal
                                            or other corrective action of the Product, or if either Party assesses that an event, incident
                                            or circumstance has occurred (in or outside the Territory) that may indicate the need for
                                            a Recall of the Product in the Territory, that Party shall advise, subject to the Quality
                                            Agreement, the other Party thereof by telephone or e-mail(a) within twenty-four (24) hours
                                            of its receipt of notice from a Regulatory Authority requiring or requesting a Recall, or
                                            (b) KNDD shall advise SCNX its determination that a Recall is needed within (24) hours of
                                            receipt of such notification, and KNDD and SCNX shall convene a joint meeting to discuss
                                            such Recall request within twenty-four (24) hours of such notification. KNDD shall include
                                            any reasonable recommendation from SCNX as to the manner of conducting the Recall, provided
                                            that such recommendation is agreeable to the applicable Regulatory Authority and in accordance
                                            with the Applicable Laws. The Parties shall memorialize and agree on the parameters of any
                                            Recall in writing. Except as otherwise provided in the foregoing, SCNX shall be responsible
                                            for the execution of any Recall related to the Product in the Territory, including communicating
                                            directly with the applicable Regulatory Authorities. If the Recall is attributable to the
                                            fault of KNDD, then KNDD shall replace the Product in question. The costs and expenses of
                                            any Recall in the Territory shall be borne solely by SCNX, provided however that to the extent
                                            a Recall in the Territory results primarily from the failure of the Product supplied by KNDD
                                            to comply with the Product Specifications, Product warranties pursuant to Section 10.2.7,
                                            and Applicable Laws, including cGMP requirements, then KNDD shall reimburse SCNX for all
                                            reasonable out-of-pocket cost and expenses incurred by SCNX as a result of said Recall. Subject
                                            to the foregoing, KNDD shall notify SCNX of any Recall of the Product outside of the Territory
                                            where the Product provided to SCNX may be part of the same Product lot(s) subject to Recall.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS, WARRANTIES AND COVENANTS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mutual
                                            Representations and Warranties</B>. Each Party hereby represents and warrants to the other
                                            Party that as of the Effective Date:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            Party (i) is a corporation (or company) duly organized and subsisting under the Applicable
                                            Laws of its jurisdiction of organization, and (ii) has full power and authority and the legal
                                            right to own and operate its property and assets and to carry on its business as it is now
                                            being conducted and as it is contemplated to be conducted by this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            Party has the power, authority and legal right, and is free to enter into this Agreement
                                            and, in so doing, will not violate any other agreement to which such Party is a party as
                                            of the Effective Date, or conflict with the rights granted to any Third Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            Agreement has been duly executed and delivered on behalf of such Party and constitutes a
                                            legal, valid, and binding obligation of such Party and is enforceable against it in accordance
                                            with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general
                                            application affecting the enforcement of creditor rights and judicial principles affecting
                                            the availability of specific performance and general principles of equity; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            execution and delivery of this Agreement and the performance of such Party&rsquo;s obligations
                                            hereunder (a) do not conflict with or violate any requirement of Applicable Laws or any provision
                                            of the articles of incorporation or formation, bylaws, partnership agreement, or any similar
                                            instrument of such Party, as applicable, in any material way, and (b) do not conflict with,
                                            violate, or breach or constitute a default or require any consent under, any Applicable Laws
                                            or any contractual obligation or court or administrative order by which such Party is bound.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
                                            Representations and Warranties of KNDD</B>. KNDD hereby warrants and represents to SCNX that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            has sufficient legal or beneficial title, ownership or license in the Intellectual Property
                                            to grant to SCNX the licenses described in this Agreement, free and clear from any mortgages,
                                            pledges, liens, security interests or encumbrances that would conflict with such licenses
                                            or otherwise affect SCNX&rsquo;s performance hereunder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the best of its knowledge, no Third Party is infringing or misappropriating, or threatening
                                            to infringe or misappropriate, any Intellectual Property in the Territory;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the best of its knowledge, the Development or Commercialization of the Product in the Territory
                                            does not infringe or misappropriate any Third Party intellectual property.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the best of its knowledge, there are no actual, suspected, pending, or threatened, adverse
                                            action, suit, proceeding, claim or formal governmental investigations in the Territory against
                                            KNDD involving the Product or the Drug Substance; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            has not granted as of the Effective Date, and during the Term shall not grant, any rights
                                            to any Third Party nor transfer, assign, license, encumber or otherwise conduct any activities
                                            with respect to any right under the Intellectual Property that conflicts or adversely affects
                                            with the rights granted to SCNX under this Agreement. KNDD is not under any obligation, contractual
                                            or otherwise, to any Third Party that conflicts with or is inconsistent in any material respect
                                            with the terms of this Agreement, or that would impede the diligent and complete fulfillment
                                            of its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            it nor its Affiliates shall develop, manufacture, market, sell, distribute or otherwise make
                                            available in the Territory during the Term of any Competing Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
                                            respect to all Product delivered by or on behalf of KNDD to SCNX hereunder, such Product
                                            will, on the date that SCNX receives the Product from KNDD in accordance with Section 7.6:
                                            (a) conform to the Specifications; (c) be manufactured and delivered in accordance with the
                                            Quality Agreement and cGMP; and (d) not be adulterated within the meaning of the United States
                                            Food, Drug and Cosmetic Act, as amended, and any regulations promulgated thereunder, or any
                                            foreign equivalent thereof in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Covenants
                                            of SCNX</B>. SCNX hereby covenants to KNDD that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            it nor its Affiliates shall, directly or indirectly, develop, manufacture, market, sell,
                                            distribute or otherwise make available in the Territory during the Term any Competing Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            shall not, and shall ensure that its Affiliates and sublicensees or licensees, will not,
                                            directly or indirectly, promote, market, distribute, import, sell or have sold the Products,
                                            including via internet or mail order, outside of the Territory. If SCNX receives any order
                                            for the Product from a prospective purchaser reasonably believed to be located outside the
                                            Territory, SCNX shall promptly refer that order to KNDD and SCNX shall not accept any such
                                            orders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Covenants
                                            of KNDD</B>. KNDD covenants to SCNX that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            it nor its Affiliates shall, directly or indirectly, develop, manufacture, market, sell,
                                            or distribute in the Territory during the Term any Competing Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
                                            shall not, and shall ensure that its Affiliates and sublicensees or licensees, will not,
                                            directly or indirectly, promote, market, distribute, import, sell or have sold the Products,
                                            including via internet or mail order, inside of the Territory. If KNDD receives any order
                                            for the Product from a prospective purchaser reasonably believed to be located in the Territory,
                                            KNDD shall promptly refer that order to SCNX and KNDD shall not accept any such orders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTELLECTUAL PROPERTY</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership
                                            of Inventions</B>. The Parties agree that all Intellectual Property and Inventions licensed
                                            under Section 2.1 shall be owned by KNDD. KNDD shall ensure that each of its Affiliates,
                                            Subcontractors and sublicensees under this Agreement has a contractual obligation to disclose
                                            and assign to KNDD all Inventions generated, invented, discovered, developed, made or otherwise
                                            created by them or their employees, agents or independent contractors. For clarity, all Inventions
                                            owned, licensed to or otherwise made by KNDD and all assigned Inventions are included in
                                            the Intellectual Property and licensed to SCNX under Section 2.1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prosecution,
                                            Maintenance and Enforcement.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            will use it best efforts to prosecute the patent applications in the Territory. If any patent
                                            should be granted, if permitted by law, KNDD shall provide the information to SCNX to list
                                            any applicable patent or patents in the FDA Orangebook as expeditiously as possible. SCNX
                                            shall assist in this process and the parties shall execute a Common Interest Agreement to
                                            enable mutual participation and visibility.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
                                            Right</B>. Each Party shall inform the other Party promptly if it becomes aware of any infringement
                                            or potential infringement of the Intellectual Property within the Territory. KNDD shall have
                                            the first right to prepare, file, prosecute, maintain and enforce the Patent Rights in the
                                            Territory, at its cost and expense. KNDD shall provide SCNX with copies of all relevant documentation
                                            so that SCNX will be informed of the continuing prosecution. KNDD shall give SCNX an opportunity
                                            to review and comment on the text of each patent application, response to Office Action,
                                            or other correspondence with any applicable patent office before filing, and shall supply
                                            SCNX and its patent counsel with a copy of such patent application or correspondence as filed,
                                            together with notice of its filing date and serial number, as applicable. In addition, for
                                            the purposes of clarity, KNDD shall separate out Third Party Infringement (where a Third
                                            Party sues KNDD) from Enforcement of KNDD IP Rights (where KNDD sues an infringer). For the
                                            purpose of this Article 11, &ldquo;<B>prosecution</B>&rdquo; shall include any post-grant
                                            proceeding in the Territory, including opposition proceedings, and other challenges brought
                                            by Third Parties in the Territory, including invalidation (nullity) actions. KNDD shall be
                                            entitled to retain any damages or other payments or benefits obtained from its enforcement
                                            of Intellectual Property in the Territory, after reimbursing SCNX for any reasonable costs
                                            and expenses actually incurred in assisting it in such action. SCNX shall use Commercially
                                            Reasonable Efforts to provide such assistance as KNDD may reasonably require in prosecuting
                                            or enforcing any Intellectual Property in the Territory. KNDD shall provide written notice
                                            (or such shorter period of time as reasonably practicable), and on receipt of such notice,
                                            SCNX shall have the right, but not the obligation, at its sole cost, to maintain such Patent
                                            Right in the Territory. If SCNX elects to assume maintenance of any such Patent Right in
                                            accordance with this Section 11.2.2, KNDD shall have the right to review and comment on SCNX&rsquo;s
                                            maintenance or enforcement efforts and the content of all filings and responses to patent
                                            authorities related to such Patent Right, and if KNDD reasonably determines that such maintenance
                                            or enforcement efforts or content of filings or responses are likely to or will disparage,
                                            limit or otherwise have an adverse impact on any Patent Controlled by KNDD, then upon KNDD&rsquo;s
                                            written request, SCNX shall modify such maintenance or enforcement efforts, filings or responses
                                            to patent authorities as reasonably requested by KNDD in order to prevent such adverse impact.
                                            If SCNX elects to assume maintenance of any Patent Right in accordance with this Section
                                            11.2.2, KNDD shall execute such documents and perform such acts as may be reasonably necessary
                                            for SCNX to maintain and enforce such Patent Right on behalf of KNDD and such Patent Right
                                            shall remain a Patent Right owned by KNDD; provided, however, that if KNDD wishes to abandon
                                            such Patent Right, KNDD shall consider in good faith SCNX&rsquo;s request to assign to SCNX
                                            the right, title and interest in and to such Patent Right, and following any such assignment
                                            it shall no longer be deemed to be a Patent Right under this Agreement and SCNX shall maintain
                                            and enforce such Patent for itself. SCNX shall be entitled to retain any damages or other
                                            payments or benefits obtained from its enforcement of Patent Rights in the Territory, after
                                            reimbursing KNDD for any reasonable costs and expenses actually incurred in assisting it
                                            in such action. KNDD shall use Commercially Reasonable Efforts to provide such assistance
                                            as SCNX may reasonably require in prosecuting or enforcing any Patent Rights in the Territory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trademarks</B>.
                                            It is agreed that SCNX shall market the Product with the Trademark and KNDD shall retain
                                            the Intellectual Property rights it may have or will have in the future with regard to the
                                            Trademark. SCNX shall only use the Trademark in a manner and form designed to maintain the
                                            high quality of the Trademark, and as otherwise communicated by KNDD, including in accordance
                                            with any trademark usage guidelines provided by KNDD. Should KNDD notify SCNX that SCNX has
                                            failed to comply with the foregoing standard, SCNX shall correct such defects in accordance
                                            with such reasonable notification from KNDD within thirty (30) days of such notice. The authorized
                                            use by SCNX of the Trademark under this Agreement shall not create any right, title or interest,
                                            in or to the Trademark in favor of SCNX. SCNX shall not register, seek to register or contest
                                            the validity of the Trademark and shall not itself use any name, mark or designation that
                                            is confusingly similar to the Trademark.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            Party Infringement Claims.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event that any Third Party otherwise files, in or out of court, any claims, demands,
                                            liabilities, or suits against KNDD or its Affiliates, alleging infringement of any patent,
                                            trademark, copyright or other proprietary right of any Third Party as a consequence of or
                                            derived from the performance of any of KNDD&rsquo;s obligations under this Agreement (hereinafter,
                                            &ldquo;<B>IP Claims</B>&rdquo;), KNDD shall give prompt notice to SCNX of the existence of
                                            such IP Claim.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            shall take proper action with respect to such IP Claims in the Territory against it and shall
                                            bear all costs, expenses and liabilities from such actions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            shall decide the defense strategy, the means of proof and the appeals in KNDD in relation
                                            to an IP Claim. KNDD shall keep SCNX reasonably informed prior to any court or administrative
                                            body filings or material exchanges with opposing counsel as to the status of such litigation.
                                            KNDD shall give SCNX an opportunity to review and comment on strategy and submissions to
                                            the court or administrative body. KNDD agrees that it shall not, without the prior written
                                            consent of SCNX, enter into any settlement agreement with any Third Party which relinquishes,
                                            waivers or otherwise effects, in whole or in part, the rights of SCNX under this Agreement
                                            in respect of a Product. KNDD may not settle or terminate such litigation without the prior
                                            written consent of SCNX, said written consent shall not be unreasonably withheld, conditioned,
                                            or delayed. Subject to Section 11.4.4, KNDD in any case shall (A) endeavor in good faith
                                            not to undertake, accept and/or plead any statement that, directly or indirectly materially
                                            impairs the Intellectual Property rights of KNDD under this Agreement or that admits: (i)
                                            an intellectual property infringement caused by KNDD or by the Product, (ii) an invalidity
                                            or nullity of KNDD&rsquo;s Intellectual Property, or (iii) any Intellectual Property is null,
                                            and (B) not undertake, accept and/or plead any statement that admits an intellectual property
                                            infringement caused by the processes for preparing the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties shall keep each other fully informed and reasonably cooperate with each other and
                                            their counsel in connection with any IP Claim in the Territory. Without limiting the foregoing,
                                            both Parties shall reasonably collaborate in the exchange of documentation and information
                                            available in order for each Party to review and take action with respect to an IP Claim.
                                            KNDD shall keep SCNX reasonably informed prior to any court or administrative body filings
                                            or material exchanges with opposing counsel as to the status of such litigation. KNDD shall
                                            give SCNX an opportunity to review and comment on strategy and submissions to the court or
                                            administrative body, such as the PTAB, provided however any final decision on strategy, submissions
                                            and otherwise related to any action in this Section 11.4.4 shall be the sole decision of
                                            KNDD.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4.5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the avoidance of doubt, in the event that KNDD does not bring an action against a Third Party
                                            infringer, SCNX shall be free to bring the action in its own name, at its own expense, and
                                            retain any award or settlement in its entirety.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Citizen
                                            Petition and Citizen Petition Litigation</B>. The JSC shall review and agree on the appropriate
                                            course of action with respect to any citizen petition proceedings and litigation specifically
                                            related to the NDA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITY</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
                                            by KNDD</B>. KNDD shall defend, indemnify and hold harmless SCNX, its Affiliates, officers,
                                            directors and employees from and against any and all claims, demands, losses, damages, liabilities,
                                            settlement amounts, costs and any expenses whatsoever arising from any claim, action or proceeding
                                            made or brought against SCNX or its Affiliates by a Third Party as a result of (i) any breach
                                            of any representation or warranty under this Agreement by KNDD, or (ii) any gross negligence
                                            or willful misconduct of KNDD, its Affiliates or its representatives in connection with the
                                            performance of this Agreement, (iii) KNDD&rsquo;s development of the Product, (iv) any claim
                                            that the manufacture of the Product in the Territory constitutes an infringement, alleged
                                            infringement, or misappropriation of any Third Party&rsquo;s intellectual property rights
                                            in the Territory, (v) SCNX&rsquo;s or its Affiliates&rsquo; authorized use of the Trademark
                                            in connection with the Commercialization of the Product under this Agreement or (vi) any
                                            violation of Applicable Laws by KNDD or its Affiliates in performing any activities in connection
                                            with the Product; in all cases, except to the extent that SCNX is obligated to indemnify
                                            KNDD under Section 12.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
                                            by SCNX</B>. SCNX shall defend, indemnify and hold harmless KNDD, its Affiliates, officers,
                                            directors and employees from and against any and all claims, demands, losses, damages, liabilities,
                                            settlement amounts, costs and any expenses whatsoever arising from any claim, action or proceeding
                                            made or brought against KNDD or its Affiliates by a Third Party as a result of (i) any breach
                                            of any representation or warranty under this Agreement by SCNX, (ii) any gross negligence
                                            or willful misconduct of SCNX, its Affiliates or its representatives in connection with the
                                            performance of this Agreement, (iii) the Commercialization of the Product in the Territory,
                                            or (iv) any violation of Applicable Laws by SCNX or its Affiliates in performing any activities
                                            in connection with the Product; in all cases, (i) &ndash; (iv), except to the extent that
                                            KNDD is obligated to indemnify SCNX under Section 12.1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
                                            Procedures</B>. If a Party or any person entitled to indemnification under this Article 12
                                            (each, an &ldquo;<B>Indemnified Party</B>&rdquo;) believes it is entitled to indemnification
                                            and defense pursuant to this Article 12, such Indemnified Party shall notify the Party or
                                            person obligated to indemnify under this Article 12 (each, an &ldquo;Indemnifying Party&rdquo;)
                                            within thirty (30) days of receipt of any claims made for which the Indemnifying Party might
                                            be liable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
thirty (30) days after receipt of such notice, the Indemnifying Party will, upon written notice thereof to the Indemnified Party, assume
sole control of the defense of such Third Party claim with counsel selected by the Indemnifying Party. If the Indemnifying Party believes
that a Third Party claim presented to it for indemnification and defense is one as to which the Indemnified Party is not entitled to
indemnification and defense under this Article 12, it will so notify the Indemnified Party. The Indemnified Party may participate in
such defense with separate counsel it selects, at its sole cost and expense (from and after the Indemnifying Party&rsquo;s assumption
of control of the Third Party claim); provided, however, that if representation of such Indemnified Party by counsel retained by the
Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and the Indemnifying
Party or any other person represented by such counsel in such action, as mutually agreed in good faith by counsel to the Indemnifying
Party and the Indemnified Party, then the Indemnified Party may participate in such defense with separate counsel it selects at the Indemnifying
Party&rsquo;s cost and expense; provided, further, that the Indemnifying Party&rsquo;s counsel shall control the investigation and defense
of such Third Party claim in accordance with this Article 12. The Indemnified Party will provide the Indemnifying Party, at the Indemnifying
Party&rsquo;s expense, with reasonable assistance and cooperation as reasonably requested by the Indemnifying Party. Without the prior
written consent of the Indemnified Party, such consent not to be unreasonably withheld, delayed or conditioned, the Indemnifying Party
will not agree to any settlement of such Third Party claim or consent to any judgment in respect thereof; further, without the prior
written consent of the Indemnifying Party, such consent not to be unreasonably withheld, delayed or conditioned, and provided that the
Indemnifying Party is in compliance with its obligations under this Article 12, the Indemnified Party will not agree to any settlement
of such Third Party claim or consent to any judgment in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIMITATION
                                            OF LIABILITY</B>. Except in the case of a breach of Article 13 (Confidentiality), SCNX&rsquo;s
                                            breach of Section 10.3.1, or KNDD&rsquo;s breach of 10.4.1, neither Party shall be liable
                                            to the other for any Consequential Damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            Other Representations and Warranties</B>. Except as expressly warranted in Article 10 (Representations,
                                            Warranties and Covenants ) or mandated by Applicable Law (without the right to waive or disclaim),
                                            each Party expressly disclaims any further warranties, express, implied or statutory, including
                                            but not limited to the implied warranties of performance, merchantability, title, fitness
                                            for a particular purpose, non-infringement of Third Party intellectual property rights and/or
                                            any other implied warranties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIALITY</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the term of this Agreement and for seven (7) years thereafter, each Party shall maintain
                                            in strict confidence all Confidential Information of the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party shall not use the Confidential Information of the other Party for any purpose other
                                            than the purposes expressly permitted by this Agreement, and shall not disclose such Confidential
                                            Information to any Third Party (including, without limitation in connection with any publications,
                                            presentations or other disclosures) except to its employees, agents or advisors who (i) have
                                            a need to know such Confidential Information to achieve the purposes of this Agreement, or
                                            (ii) except as authorized under this Agreement or by the other Party in writing. Each Party
                                            shall ensure that any person to whom it discloses the other Party&rsquo;s Confidential Information
                                            is informed of the confidential nature of and duty not to disclose the information, and is
                                            obligated to maintain the confidentiality thereof. Each Party may also disclose the Confidential
                                            Information of the other Party as may be required by the Applicable Law or by any Regulatory
                                            Authority having jurisdiction, provided that the Party required to disclose shall, if possible,
                                            notify the other Party prior to disclosing any Confidential Information and provide such
                                            other Party with a reasonable opportunity to contest or limit the scope of the required disclosure
                                            and obtain any protective orders as may be appropriate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            as otherwise provided herein, upon termination or expiration of this Agreement, each Party
                                            shall destroy or, if so requested in writing, return all Confidential Information of the
                                            other Party and certify in writing that such return or destruction has been completed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORCE MAJEURE</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
                                            Party shall be liable to the other Party for damages arising from the failure to perform
                                            the obligations assumed in this Agreement when such failure shall be occasioned by Force
                                            Majeure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            Party affected by a Force Majeure shall, within fifteen (15) days of the occurrence of the
                                            Force Majeure event, give reasonable notice to the other and shall endeavor in good faith
                                            to minimize the effects of Force Majeure on this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            this Agreement is suspended for more than six (6) months by reason of Force Majeure, either
                                            Party shall have the right to terminate this Agreement on the terms and conditions as are
                                            provided for in Section 16.1.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            Agreement shall be effective upon the Effective Date and shall continue in effect for a period
                                            of ten (10) years from the Launch Date of the Product in the Territory, unless earlier terminated
                                            in accordance with Section 17 (the &ldquo;<B>Term</B>&rdquo;)<I>.</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
                                            the Term of this Agreement shall be renewed for successive periods of one (1) year unless
                                            either Party delivers notice to the other Party of its intention not to renew the Agreement
                                            in writing at least six (6) months prior to the expiration of the then-current Term.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERMINATION</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mutual
                                            Rights</B>. Either Party shall have the right to terminate this Agreement immediately upon
                                            prior written notice in any of the following cases:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event that (i) the other Party hereto shall (1) apply for or consent to the appointment
                                            of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself
                                            or of all or a substantial part of its property, (2) make a general assignment for the benefit
                                            of its creditors, (3) commence a voluntary bankruptcy, (4) file a petition seeking to take
                                            advantage of any law relating to bankruptcy, insolvency, reorganization, winding-up, or composition
                                            or readjustment of debts, (5) fail to controvert in a timely and appropriate manner, or acquiesce
                                            in writing to, any petition filed against it in any involuntary bankruptcy case, or (6) take
                                            any corporate action for the purpose of effecting any of the foregoing; or (ii) if a proceeding
                                            or case shall be commenced against the other Party hereto in any court of competent jurisdiction,
                                            seeking (1) its liquidation, reorganization, dissolution or winding-up, or the composition
                                            or readjustment of its debts, (2) the appointment of a trustee, receiver, custodian, liquidator
                                            or the like of the Party or of all or any substantial part of its assets, (3) similar relief
                                            under any bankruptcy laws, or an order, judgment or decree approving any of the foregoing,
                                            and such proceeding or case shall be entered and continue unstayed for a period of sixty
                                            (60) days, or (<STRIKE>4</STRIKE>) an order for relief against the other Party hereto shall
                                            be entered in an involuntary bankruptcy case.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            the event of a Force Majeure that lasts for more than six (6) calendar months and either
                                            Party finds it impossible or impractical to perform its obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the other Party commits a material breach of any term of this Agreement and fails to cure
                                            such breach within the ninety (90) days following written notice of such breach from the
                                            non-breaching Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNDD&rsquo;s
                                            Rights</B>. KNDD shall have the right to terminate this Agreement in the following cases
                                            (in addition to those set forth in Section 16.1):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
                                            with respect to the Product: there is a withdrawal from the market of the Product due to
                                            (i) any decision, judgment, ruling or other requirement of the FDA, (ii) the issuance of
                                            a voluntary recall by FDA, or (iii) material safety concerns, in each case which could significantly
                                            impact the commercial viability of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNDD
                                            shall have the right to terminate this Agreement immediately if the Product becomes the subject
                                            of any mass tort liability action or there are material health and public safety concerns.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCNX&rsquo;s
                                            Rights</B>. SCNX shall have the right to terminate this Agreement in the following cases
                                            (in addition to those set forth in Section 16.1):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            one hundred and twenty (120) days prior written notice to KNDD, SCNX shall have at its sole
                                            discretion, the right to terminate this Agreement if the value of the Product is compromised
                                            by an adverse and material change in market or other adverse and material business conditions
                                            (as evidenced by written records reasonably acceptable to KNDD). Unless otherwise mutually
                                            agreed in writing, SCNX shall not have a right to terminate under this Section 16.3.1 during
                                            the pendency of any dispute over SCNX&rsquo;s right to terminate or KNDD&rsquo;s response
                                            to evidence provided by SCNX under this Section 16.3.1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
                                            with respect to the Product: there is a withdrawal from the market of the Product due to
                                            (i) any decision, judgment, ruling or other requirement of the FDA, (ii) the issuance of
                                            a voluntary recall by FDA, or (iii) material safety concerns, in each case which could significantly
                                            impact the commercial viability of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCNX
                                            shall have the right to terminate this Agreement immediately if the Product becomes the subject
                                            of any mass tort liability action or there are material health and public safety concerns.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EFFECTS OF TERMINATION</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNDD
                                            Right to Terminate</B>. If KNDD is entitled to terminate this Agreement pursuant to Sections
                                            16.1.1 or 16.1.3 (subject to applicable notice and cure periods), KNDD shall be permitted
                                            by written notice to SCNX to terminate this Agreement with the effects set forth in Section
                                            17.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCNX
                                            Right to Terminate</B>. If SCNX is entitled to terminate this Agreement pursuant to Section
                                            16.3.2 occurring prior to Launch; or Section 16.3.3, SCNX shall discuss in good faith with
                                            KNDD its ability to receive the grant of a license to SCNX for a different product in KNDD&rsquo;s
                                            Development pipeline, under terms to be negotiated at the time of occurrence; the parties
                                            shall have a good faith discussion to apply any milestone payments paid by SCNX to KNDD for
                                            the Product to be used as a credit for any payments due to KNDD for the grant of the new
                                            license.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
                                            SCNX terminate this Agreement for any reason prior to KNDD receiving full payment for the
                                            NDA, within thirty (30) days of said notice of termination, SCNX shall assign the NDA back
                                            to KNDD.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
                                            or Expiration</B>. Except as expressly stated in Sections 17.1 and 17.2, in the event of
                                            any expiration or termination of this Agreement, whether by SCNX or KNDD, the following shall
                                            apply:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4.1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                            for the right of SCNX and its Affiliates to exercise their rights and perform their obligations
                                            under this Section 17.4, the licenses and other rights granted by KNDD to SCNX under KNDD&rsquo;s
                                            Intellectual Property will terminate ;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4.2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            outstanding sublicenses under any of the licenses granted by KNDD to SCNX hereunder shall
                                            terminate unless otherwise agreed in writing by the sublicense and KNDD;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4.3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            Commercialization activities of SCNX and its Affiliates and their sublicensees with respect
                                            to Products shall cease; provided, that SCNX and its Affiliates may, for up to six (6) months
                                            after termination, sell on a non-exclusive basis any existing inventory of Products in SCNX&rsquo;s
                                            possession or control or delivered to SCNX under this Agreement following such expiration
                                            or termination, subject to SCNX&rsquo;s payment obligations under Article 6;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4.4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                            limiting any of the foregoing, the Parties shall cooperate to effect an orderly wind down
                                            and transition to KNDD or its designee of activities under this Agreement or otherwise related
                                            to the Product in accordance with Applicable Law and accepted pharmaceutical industry norms
                                            and ethical practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
                                            Rights</B>. Expiration or termination of this Agreement for any reason shall be without prejudice
                                            to any right which shall have accrued to the benefit of either Party prior to such expiration
                                            or termination, including damages arising from any breach under this Agreement or liabilities
                                            or obligations which accrued hereunder, in either case, prior to the effective date of such
                                            expiration or termination. Expiration or termination of this Agreement shall not relieve
                                            either Party from any obligation which is expressly indicated to survive such expiration
                                            or termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Survival</B>.
                                            The following articles and sections, together with any sections that expressly survive or
                                            that are required to interpret such articles or sections, shall survive expiration or termination
                                            of this Agreement for any reason:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLICABLE LAW; DISPUTES; JURISDICTION; JURY TRIAL</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            validity, interpretation and execution of the Agreement, including the rights and liabilities
                                            of the Parties hereunder shall be governed by, and construed in accordance with the laws
                                            of the State of New York, except for any choice of laws rules that would result in the application
                                            of the laws of any other jurisdiction. The Parties expressly agree that the United Nations
                                            Convention on Contracts for the International Sale of Goods shall not apply to this Agreement
                                            or any Party&rsquo;s performance hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            dispute controversy or claim arising out of or relating to this Agreement, that cannot be
                                            settled in an amicable manner shall be submitted in the first instance to the Executive Officers
                                            of the Parties, who shall meet in person or by teleconference or videoconference to discuss
                                            the same within thirty (30) days of the receipt by one Party of formal written notice of
                                            dispute from the other Party. If the senior Executive Officers are unable to resolve the
                                            dispute within such time period, then each Party reserves its right to any and all remedies
                                            available under law or equity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            disputes arising in connection with this Agreement that cannot be settled in an amicable
                                            manner or by senior executives from the Parties shall be exclusively settled and resolved
                                            by the United States federal courts located in the State of New York. Each Party further
                                            agrees that service of any process, summons, notice or document by U.S. registered mail to
                                            such Party&rsquo;s respective address set forth in Section 16.1 of this Agreement shall be
                                            effective service of process for any action, suit or proceeding in New York with respect
                                            to any matters to which it has submitted to jurisdiction in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Party hereto waives, to the extent permitted by Applicable Law, any right it may have to
                                            a trial by jury in respect to any litigation directly or indirectly arising out of, under
                                            or in connection with this Agreement, and each Party hereto (i) certifies that no representative,
                                            agent or attorney of any other party has represented, expressly or otherwise, that such other
                                            Party would not, in the event of litigation, seek to enforce that foregoing waiver, and (ii)
                                            acknowledges that it and the other Party hereto has been induced to enter into this agreement
                                            by, among other things, the mutual waivers and certifications in this Section 18.4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICES</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            notices or other communications to be served or sent to either Party shall be in writing
                                            and shall be sufficiently sent if delivered in person, by registered prepaid airmail or address
                                            as set out below or such other fax number or address as such Party may notify in writing
                                            to the other Party from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    to SCNX</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If
    to KNDD</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20
    Austin Blvd</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">_1513 Bull Lee Road</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commack
    NY</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">_Lexington, KY 40511</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11725</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    General Manager</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    President and CEO </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kindeva
    Drug Delivery</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11200
    Hudson Road</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodbury,
    MN 55129</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    General Counsel</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            such notice shall be considered to have been given at the time when actually delivered or,
                                            in the case of a fax, on completion of the transmission or in any other event within seven
                                            (7) days after it was mailed in the manner provided above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assignment</B>.
                                            This Agreement shall be binding upon and inure to the benefit of the successors or permitted
                                            assigns of each of the Parties and may not be assigned or transferred by a Party (other than
                                            to an Affiliate) without the prior written consent of the other, except that such consent
                                            shall not be required on the part of either Party in connection with a Change of Control;
                                            provided, that the successor or assignee in such Change of Control assumes in writing all
                                            of the obligations imposed herein and; provided, further, that in the event of a Change of
                                            Control of KNDD, (1) assignee or successor makes a good faith offer to purchase SCNX&rsquo;s
                                            rights solely with respect to the Product, which SCNX may choose to exercise in its sole
                                            discretion, and if the offer is not accepted by SCNX (2) that the successor or assignee in
                                            such Change of Control assumes in writing all of the obligations imposed herein. Any attempted
                                            assignment that does not comply with the terms of this Section 20 shall be void.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Entire
                                            Understanding</B>. This Agreement is the entire understanding and agreement between KNDD
                                            and SCNX relating to the subject matter hereof and supersedes (except as provided herein)
                                            any and all prior arrangements, understandings and agreements between KNDD and SCNX whether
                                            written or oral relating thereto. No amendments, changes, or modifications of the terms of
                                            this Agreement shall be deemed valid and binding unless made in writing and signed by the
                                            duly authorized representative of each Party hereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent
                                            Contractors; Expenses</B>. The KNDD and SCNX hereto agree that in connection with this Agreement
                                            the status of each of them in relation to the other is that of an independent contractor
                                            acting in its own name and for its own account. Accordingly, neither the KNDD nor SCNX have,
                                            or will be considered to have, any power of authority to act as an agent or representative
                                            of the other, nor have any power of authority to contract in the name, or create or assume
                                            any obligation or liability against, or otherwise legally bind the other in any way for any
                                            purpose, unless otherwise expressly provided herein, or otherwise agreed separately in writing.
                                            All costs and expenses connected with the activities and performance of each of KNDD and
                                            SCNX under this Agreement are to be borne solely by KNDD and SCNX, as each incurred such
                                            costs and expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-waiver</B>.
                                            The failure by any Party at any time to enforce any of the terms, provisions or conditions
                                            of this Agreement or to exercise any right hereunder shall not constitute a waiver of the
                                            same or affect the validity of this Agreement or any part hereof, or that KNDD&rsquo;s and
                                            SCNX&rsquo;s right thereafter to enforce or to exercise the same.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severability</B>.
                                            In case one or more of the provisions contained in this Agreement shall for any reason be
                                            held invalid, illegal or unenforceable in any respect, such holding shall not affect any
                                            other provisions of this Agreement. Instead, a provision shall be construed by limiting such
                                            provision to such extent as would nearly be possible to reflect the intent, purpose and economic
                                            effect of such, or, if such is not possible, by deleting such provision from this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex1-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>English
                                            Language</B>. This Agreement has been written and executed in the English language as used
                                            in the United States of America and shall be interpreted in accordance with the English language
                                            as used in the United States of America. Any translation by a Party into any other language
                                            shall not be an official version thereof, and in the event of any conflict in interpretation
                                            between the English version and such translation, the English version shall control.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.7</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Injunctive
                                            Relief</B>. Either Party may seek immediate injunctive or other interim equitable relief
                                            as necessary to enforce the terms of this Agreement, provided that such relief is sought
                                            exclusively from a court as provided in Article 18 hereof. The Parties hereto acknowledge
                                            and agree that any breach damages would not be an adequate remedy and accordingly the Parties
                                            agree that, in addition to any other remedies, each Party shall be entitled to obtain preliminary
                                            or injunctive relief and to enforce the terms of this Agreement by a decree of specific performance
                                            without payment of a bond or surety.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Third
                                            Party Rights</B>. Nothing in this Agreement will be deemed to create any Third Party beneficiary
                                            rights in or on behalf of any other person or entity.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Further
                                            Actions and Documents.</B> Each Party agrees to execute, acknowledge and deliver all such
                                            further instruments, and to do all such further acts, as may be reasonably necessary or appropriate
                                            to carry out the intent and purposes of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Counterparts;
                                            Facsimile/PDF Signature.</B> This Agreement may be executed in any number of counterparts,
                                            each of which shall be an original, but all of which together shall constitute one instrument.
                                            This Agreement may also be executed via facsimile or PDF, which shall be deemed an original.
                                            Such counterparts may be exchanged by facsimile or PDF (provided that each executed counterpart
                                            is transmitted in one complete transmission or electronic mail message).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the date first
above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summit
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ David
  Stevens</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Stevens</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REASON: I approve this document</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04 Mar 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scienture,
LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Narasimhan
  Mani</I></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Narasimhan Mani</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 4, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to License Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">CONFIDENTIAL</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCIENTURE
to commercially launch REZENOPY&reg;, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY
L.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAMPA,
FL, March 06, 2025 (GLOBE NEWSWIRE) &mdash; SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), </B>a holding company for existing and planned pharmaceutical
operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market,
and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, <B>Scienture,
LLC (&ldquo;Scienture&rdquo;)</B>, has entered into a definitive agreement with <B>SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary
of Kindeva Drug Delivery L.P. (&ldquo;Kindeva&rdquo;))</B>, for the exclusive U.S. rights to commercially launch REZENOPY<SUP>&reg;</SUP>
(naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY<SUP>&reg;</SUP> (naloxone HCl) Nasal Spray
10mg. Scienture will own the new drug application (NDA) for REZENOPY<SUP>&reg;</SUP> in its name and be responsible for the sales, marketing
and distribution of the product in the U.S. through Scienture&rsquo;s commercial operations infrastructure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REZENOPY<SUP>&reg;
</SUP>is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of
the active ingredient and form factor, with increased effectiveness against potent opioids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
addition of REZENOPY<SUP>&reg;</SUP> to Scienture&rsquo;s product portfolio aligns with Scienture&rsquo;s mission to provide innovative
treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in
advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose.
As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and
advocacy groups to enhance awareness, education, and distribution efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasal
delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for
first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189
million, unit volume of $10.0 million (eaches) for Naloxone in the US market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are proud to take this significant step in strengthening our commitment to combating the opioid epidemic,&rdquo; said Narasimhan Mani,
Ph.D., MBA, President of Scienture, LLC. &ldquo;Through this collaboration with a well established and strong partner like Kindeva, we
now offer REZENOPY<SUP>&reg;</SUP>, a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare
solutions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
collaboration is not just about expanding our portfolio; it&rsquo;s about making a real difference in the fight against opioid addiction,&rdquo;
added Shankar Hariharan, Ph.D., CEO of Scienture, LLC. &ldquo;By working alongside public health agencies and community organizations,
we will drive meaningful change and save lives.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;As
part of our commitment to fast-tracking healthier tomorrows, we are thrilled to be joining forces with Scienture to bring this life-saving
device to market,&rdquo; remarked Milton Boyer, CEO of Kindeva. &ldquo;Our nasal drug delivery team has created a nasal spray that is
quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States. We are dedicated
to ensuring this device reaches the people that need it most as quickly as possible and prevent more opioid related fatalities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
REZENOPY<SUP>&reg;</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REZENOPY<SUP>&reg;
</SUP>(naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose,
as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration
as emergency therapy in settings where opioids may be present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REZENOPY<SUP>&reg;
</SUP>nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray
device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMPORTANT
SAFETY INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Administration:
                                            </B>REZENOPY<SUP>&reg;</SUP> nasal spray is for intranasal use only. Seek emergency medical
                                            care immediately after use. Administer a single spray into one nostril. If the patient does
                                            not respond within 2 to 3 minutes or responds and then relapses into respiratory depression,
                                            an additional dose may be given into the other nostril with a new device. Do not administer
                                            more than 2 sprays per day. Additional supportive and/or resuscitative measures may be helpful
                                            while awaiting emergency medical assistance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contraindications:
                                            </B>REZENOPY<SUP>&reg;</SUP> nasal spray is contraindicated in patients known to be hypersensitive
                                            to naloxone hydrochloride or to any of the other ingredients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warnings
                                            and Precautions:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
                                            of Recurrent Respiratory and CNS Depression:</B> Due to the duration of action of naloxone
                                            relative to the opioid, keep the patient under continued surveillance and administer additional
                                            doses as necessary while awaiting emergency medical assistance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
                                            of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists:</B> Reversal of
                                            respiratory depression caused by partial agonists or mixed agonists/antagonists, such as
                                            buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Precipitation
                                            of Severe Opioid Withdrawal:</B> Use in patients who are opioid-dependent may precipitate
                                            opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized
                                            and properly treated. Monitor for the development of opioid withdrawal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
                                            of Cardiovascular Effects:</B> Abrupt postoperative reversal of opioid depression may result
                                            in adverse cardiovascular effects. These events have primarily occurred in patients who had
                                            pre-existing cardiovascular disorders or received other drugs that may have similar adverse
                                            cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting
                                            after use of naloxone hydrochloride.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adverse
                                            Reactions:</B> The following adverse reactions were observed in a REZENOPY<SUP>&reg;</SUP>
                                            nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Storage
                                            and Handling:</B> Store REZENOPY<SUP>&reg;</SUP> nasal spray in the blister and cartons provided.
                                            Store between 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Excursions permitted up to 40&deg;C
                                            (104&deg;F). Do not freeze or expose to excessive heat above 40&deg;C (104&deg;F). Protect
                                            from light. REZENOPY<SUP>&reg;</SUP> nasal spray may freeze at cold temperatures. If this
                                            happens, the device will not spray. If REZENOPY<SUP>&reg;</SUP> nasal spray is frozen and
                                            is needed in an emergency, do NOT wait for it to thaw; get emergency medical help right away.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more detailed information, please refer to the full prescribing information provided by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Scienture Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCIENTURE
HOLDINGS, INC. (NASDAQ: &ldquo;SCNX&rdquo;), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC,
is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering
novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells
brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies
nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals
who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare
systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and
channels. For more information please visit <U>www.scienture.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Kindeva Drug Delivery L.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kindeva
Drug Delivery is a leading global powerhouse CDMO for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dose.
We are committed to manufacturing more tomorrows for our customers, colleagues, and patients around the world. We deliver unrivaled expertise
across development, manufacturing, and comprehensive analytical services for a broad range of drug-delivery formats. Through strategic
investments in cutting-edge technology, we proactively tackle critical industry challenges, including expanding aseptic injectable fill-finish
capabilities and leading the way in green propellant initiatives. Combining forces with a diverse global client base, Kindeva operates
state-of-the-art manufacturing, research, and development facilities across the U.S. and U.K. For more information please visit <U>www.kindevadd.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Statements Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains certain statements that may be deemed to be &ldquo;forward-looking statements&rdquo; within the federal securities
laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking
statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,
our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management
team&rsquo;s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and
the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations
of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify
forward-looking statements by the following words: &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; or the negative of these terms or other similar expressions, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number
of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different
from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking
statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed,
and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests
under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims
relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal
proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks
detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCIENTURE
HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCIENTURE
HOLDINGS, INC.<BR>
6308 Benjamin Rd, Suite 708<BR>
Tampa, Florida 33634<BR>
Phone: (866) 468-6535<BR>
Email: <U>IR@Scienture.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex1-1_001.jpg
<TEXT>
begin 644 ex1-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( % # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^O#]M+X]:
MWX#&B?#KP?J,^C:SXBTV;7-?UVRD:UU+3=$:Z?3].L=)N8QYMI=ZM<1:A+=Z
MA#)%=6%MI]O%;?O-3,]M^5\FJ^?)))---*\S,\TLLAFEDD9MS-,\I=I&=F9Y
M&D=R[.S$EF8M]B_\%$O#VIZ)\1?!GCKR))= \4>&D\-?;0DC0V>O^';F]O?L
M%PY4PP/J.E:FEWIT<CQO<'3M7,*RM;3&/\\CKB\ JJG'.Y5Z$\@@(,'.0?H<
M],U_E?\ 20\(L[\3/%'/<9Q++%YCE^63HX+AK+,3+$/+,NRB6"PDHSP& <YX
M+VF8U*E;%X_%TZ"Q6-KPI?6<3*.!PF'PWQ>8\>O)L?B<NE)4'2E!RBFH\\)P
MHU:-5RMS2@XU/<M*4/>7NJ;/TR_8\_: UVQ\9Z7\*_$FJ7FM>'_$RRV?AJ34
MKF>^O/#NL6UO-=065K>7&^8Z1JD,,ELVGRRF&RNX[2:P:*.6ZMY/MC]I?XNW
M?PA^';ZIHJ02>)M>U"/0/#SW,:R16E[);3W=SJSVY#BX_LNQM;F:&WD3RGNI
M+-9RT1,4GY'?L@:%J7CC]H#P0--MI'M/"%V_C/Q!=HN8K#2]-AFAMVN&"XA-
M_J4D%E:*Q!GE6X6/<+><Q_HW^W/X4U/6/AKHGB*QA::'P5XB>]U=%!_=Z3JU
MHVE2WV<$+'8WGV W$CC9%;SR2R.B1LQ_2L!B?$_PU^B)XGRR/%YOB<\X3RW,
MZ7!N/KK%9CF>4Y#)9 LWJX&OC8XW%5H<,X#%\0XW*95IYBLNI86<,-_LN64,
M/@?I^&,WH\10ACII*A+$SH^T3485Y4X/FDFERN*KM4ZDU>\U4YI\W,X_D?XJ
MU?5M=O[K5M>U;4]<U6^(EN]1U>\GOKV=\;?GN+B21D1,A4@C800(1' J1*JU
MTOP0_:0\8?L_^,+#4+:[U+5_ -U=0)XM\$F[:6TN=/E(2YU70K6Z8VFF^([%
M9/M-M<6K60U5XH[#4Y9(7CEM>*U4D@>N$)R&S\V,9R>,A3UQC X-<#!X<UWQ
MIXBT3PCX6TV;5_$?B+4+;1]&TV$JC75[<D;-TSXBM[>%8Y+F\O)F%O:6<%U<
MRN([=\?FGT8L?F,,1E6.IXK%SS'$3HUIXCZSBL3B<75Q$85:LJ]:KB,3B,P>
M)E4D\0\5B<9+%*3JUZU=M8B7Y/XA8S'X#'1QF5U:U/,*&+2PGL7.4ZN(G6C3
MI89THV>(AB9R]@\-)RAB(OD=DE*/[2_%3_@HK^S/X)^'FI^+-"\:6WC?Q'!I
M[76@^ =-L]7L]=UK5C&'LM)U&:\TY8O#ML;H)!J^J727']F0-/<6]EJ5S#%8
MW7\H_P ;OCC\4/CYXVO?'/Q5\7:GXFUR22\_L^UENKI?#?AFRN) \FC^$?#S
MW,^G^'-*0I J6]B@GO4A@GU:[U&]4W;?LO\ &'_@EC\:=*^'VI^*?#?C7PGX
MY\2Z3I]QJ5S\/-)T/6M/O+U;>,S3:?X7\07EW<1Z[J9VE+*SN?#^@-?LHBMF
M:ZDM[2;\";@J\Q:-LK)O="RF,E7(92P?!#8(#)]Z-MRN RD#_=SZ/N#P5?%U
M,=7HTO[4@J$9RDHRJX15-9TZ2ES.C"K\4Y1<O:\BIRJN,?9/_+[Z=?''C#F&
M-X4X=XQRW$\+<+UJ&-QN RK 5*U/*^(<50J8:G5S#,9PQV)I8_%X'VE*%'+,
M1.=/)X8KZQ##/$8Q9@O4?@I\?/BM^SSXTLO''PG\7:GX:U>VEMFO]*-W>S^%
M/%5I [NNC^+O#\=Y;6.MZ8RM+$D<T1O;4SO/IE]IMV$NA_:Y^SY\7=&^//PE
M^'OQ>T"QETS3/'OA>SUU-+GD2XET:\D+6VJZ(]ZB0"];1]6M[[3!>"UM5O%M
M!>+;P+.(Q_"%)'@RMRRKM:8JF]5178*0R;F9W9ML<<:,TCL(XU=W5#_;1^P?
M\+?$?P:_95^"GP_\7VCZ=XJTSPB=3\1:5<,ZW>C:IXDU34?$4VB7<#;Q;WNC
MQZG#IVH6\<KQP:C;7<2,RJ'?])^E-DW#M+AS@_/XT<)0XJQ.;8G+'5I1I1Q.
M99/1RQ8G%?6I4E"5=95C)9?]7Q%7ZQ4I2S">!]JH3C2H_?\ [.#B+C*OGG'?
M"\\1C\1P+@<BR[-HX>O.O7P&4<18C-G0PWU&5>K4A@JN;Y<\RJ8O"8=4(8NG
M@*.95*$ZN'AB:OT?XV\%^%/'GAC5/"GC'0[#Q%X=U:)8K[2M14O#.L;++#)'
M(CK-;WD#K'+:W<#I<6\J(\+JU?S!_'?PSI_PJ^.7CWX3Z/JYNK'0O%EKHVC:
MAJC^=/;66M1:?<V$6JR(\?GS:2FJ);75SN22Y2U^TR?O)7C'ZU?\%&OV[+G]
MDKPUX=\+> [/3=7^+GQ#M-0N]%?58S=Z9X)\,Z5<0V=UXNU73D8-JEY?7TXT
MOPKI$S6]G?WEAK>H7<MQ9Z)<Z?=_RT^(OB?XJ\6:MKGB#Q1J-[K^N>);^_U/
MQ!J>J.TU_JU]JCM+>W=ZPC6)I)V<IY2*D,$*QVL$<=K!!&O\N9-X.XWC?+Z>
M:8G+Z,,%*52&!Q%6-J^)4)U8590<(1J+#PJ*:4Y3Y9U>=15^9O\ 6?I<?22X
M&X-SW+>",!&OFG&N3XBCC.(:V$HI4,HR[%8*CB:&1XC%RJ4O;YCF$*M#&U<+
M24X991E0G7Q-*OBUAC^W/X,_!/P!\#?"T?A?P3ID5NTBVYU[7;@B77_$^I6,
M1MQJ6MWY >9PSW$EK9Q&*PTQ;F:#3[6!&D,OKUS:V]U;2VMS!%<6UTDEO<07
M")-!/#.K12P3P2JT4T,T;O'+%(K)(C,C*RN5K\*/^":'_!1'Q7\4O$EA^SS\
M<;]-4\2RZ2Y^&_CZ9VAU?Q%_85E++>^%O%X8F.^UP:5;RZCH7B6)5FUA;34=
M/UN#^TUTW4-2_2C]LC]J7P_^R?\ !#7/BEJ5BFNZT^H6/AKP3X8FN_L">(_%
MNKI<-865Q>+'++!I=C9VM]K6M7%M%+<)I.F7:6RBY>%UX*W F=X3/LOX*HY1
MSYMF%7"8#*\NPU.#IXUXZ?LL-'#7C"A.A4YJOM93M3IJGC/K/NTZ_/\ U+X?
M^-GAEQ9X53\3\AS.&5<%9%E^-GG-/&T)87$\,SR;"T:V8Y=F.#I^WG]:H0JX
M:>&>'GBO[7AC<%B<'4K5,P<*7&^,_P!A'X.>)=4GO=,U;QCX)CN"S-I?AN_T
M>[TU&8EA]EM_$.BZQ)9QH>$MH)S;*HVK&$ 0>L_!;]F3X4_!&>XU3POI]YJ/
MB6]M19W/BOQ'=QZCKQLW<&:UL7BM[.RTJUF**;F+3;&T-T$C%PTB1QHG\A'Q
M-_;J_:T^*GB&X\0Z[\=/B!HSSO.]MHG@;7-3\ >&M-AD(VP:9I'AB]L9%A11
MUU2^U:\9AOFOYW9Y&^Y_V&?^"IWQ5\"^._#'P[_:'\97GC_X8^*=6TSP['XQ
M\3F&3Q+\/KW5+JWT^PU:36D@CN-8\-0W$L,?B.VUM[ZZLK)Y-<L-2LQIU[9Z
MI^D_\2 8KPYRC'\8<,9/P)/.:%"OC\PR3AK"8_#X[#Q5.K5Q\\IJ8EQR;%58
M14Y1HY7A,K^LT_;/+Z+]S"2_G/A7Z=W@OQ3Q[@\EQO#?$/#^'QF/IY?E?&.=
M4\JJ8.&(Q->EA<)5Q^"PF,KXS)Z&*JUZ5.6,E+'/ ^WC/&*G0AC*V%_J;DB0
M$'&"""&R>"#QG&"#R<$'MVQQ^:G[17_!+O\ 9I_: \77OCR>/Q1\,/%^L7<]
M_P")-7^&]]HMG9^)-0N97FNM0U3P]XAT+7]$_M>]E=IK[5=/M+"]O97>>\>X
MG9Y#]U_$WXC^%?A?X!\7_$/QGJ#Z5X7\$:%J7B'7[V.,S30V.EPRRO#:0!D-
MUJ-W*B6.F6*.)+_4+BULXCYEPE?R*_M$_P#!2K]I[XZ>*=1O]'\=^(O@]X#D
MG(T+P'\.M=N-%GTZP,C26BZ[XOTQ;'6_$FM+&ZMJ-W'<6&DM<&9--TJUM!%N
MY_!K@#C?C7-<3CN$,YP_#.&RJG2IXWB'%XC%4J$*F)7M:& P^&PE#$U\RQ$Z
M49XJ>&="%&A15*O4KPJ3ITW^C?2I\4_!/@7AO+,E\7.%*'B!5SNM6QF1\(0P
MF"Q&-7U"HL/BLX^NXROA/[#HX>M5IX*GC*.-I8O%UZE3"T,/B*-#%2I_OQ^S
MK_P2^_9G^ 'BW3O'MM#XE^)WB_1K^#4?#VL_$;5-'O[7PUJ%K/&]GJ.D>'M!
MT'PYH*ZQ8R*T^GZO?V5]J.G3-Y]E<17*0SQ_IHBQJ^4SN8-\Y8L>I;G/)P23
MZ#)'I7\;7[.7_!2O]IKX$^)=-FUWQOXC^,G@$WZOX@\"_$/6)M<O+^Q>0&[7
MPWXMU1[G5] USRB6L)[F[NM&:X6*WOM/DM7D=/Z[/AIXZ\._$WP3X3^(/A#4
M5U;PQXT\/:;XET#4!$8FGTO5[:*\M!<0L[/;W<*2B"]LW;S+.]BN;64B6)E6
MO&C@?C_A+-\!C>-<\7%E#,:<\+E/$5+$XFM0G'"QC4J9;+"XJE0K956H4JL,
M1'#.A"AB:3G7H5:]2%=I_18\5/!3CSAO,LF\).%<-P#7R2M1QN>\'?4\'A\7
M2CCI3PV&SE8_!UL5'/L/B*F'>$ECZN,J8K!UHTL)7PV'ISH\_P#,[_P6HT36
MM)_::\#^)+^*X?0/%/PCTNU\-W,L31133^%O$.LV_B/3K67.V672)M8TC4K]
M$/\ HJ>*M*+Y%Y#7XZFX. /*Z;@2&)7YC\OS \CM][G/3K7]Q'[4?[*_PN_:
MM^'$GP_^(]G?6PM+U=5\*^*]!:W@\2^#==,,EL^J:-<7EO=V;K<6\S6VIZ9?
M6MSIFK6NR"]MG>&TFM_PGU?_ ((<?&B#6&M=$^-WPGU+P\98EBUK4]$\:^'M
M6:$,!-,_A2T@\76:S1+@Q6J^-YX[EC@W5JJ\_N?@WXJ^&M'@W+<BXOS6GP[F
MN14IX.-3%8/'U\%F>"]OB*V'Q&&Q. P6/MB_9U_98K"5Z-&I4JPC6HUY0FU#
M^*/I2_1!\5\]\6.(^..!,D?&&2\:8Z&;SIX/'Y5A<RR7,ZV%P5#'8''87,LR
MRN57"^WPCKX+,,/6Q4/J]:>'Q5*A7PT'B?A__@GGH^M>)/VT/V>;30H)I+RP
M\;C7[]XF9Q;Z!X>TC4K[6KJ?:5(MHK13%(P8JS744;;@RH_Z_?\ !<SPYX@U
M#X-?!/Q+I\5Q<^'O#GQ/U?3_ ! L<8\FRO?%'A:6W\.W]TXVK$GVC2M2TBW=
MN#=ZS!!N#2HC?;/[%7[!/PV_8VTC5=0TO6;SX@_$_P 3Z;:Z5XF^(FK:5!HS
M?V9:W O$T'PIX?AO]4B\+:!/>)%>ZA:/K.LZGJ]Y;Z?-K&L7:Z7IL%I]@?$[
MX:^"?BUX$\3?#GX@>'[;Q'X/\6Z=)I6MZ3<M+&)K=V$T4UO<0,MS9:A97<,%
M[I^H6LL-W87]M;W5O+%-"IK\XXB\9,DH^-'"O'/#N JYAP]P?4H82,:]&6#Q
M6<X6O_:,,XQ-##U^6M@VZ>9UEE5/%>SJ16%HU*RP\<5*E0_H_P )?HJ<09#]
M&3C[PKXDS3"Y=Q=XD.KFV(A0Q"Q^6</8["X;*X</8"OB,*U#&PC+)J#SJM@G
M4H)8ZI1P57$?4G*O_ 'R,8/)VD 9)7R^&W'I[KM)!&>3Q4L&DZEXDEA\-Z)I
MMSJFL^(IX] TG2[;:UQK&K>()HM(T;2[1#Q]JU+4;NWL[89YFG3H"2/WA^)G
M_!#GQ[%XDO)?A#\:O".K>$[JXGFLK'XF:1KWA_Q-HD3,!#:76L^$M*\2Z5XH
M<8D,FI1Z)X2<H(PVFRS.]S)]J_L4?\$J/!G[-/BG3/BK\2?%EO\ %?XHZ6XF
M\-+IVA3:!X)\$7TD303ZEI]G?WFI:KXC\10)+/#9>(M2?1[:QMYFDL?#EE>[
M[]_Z]S_Z4OA+E_#E?-<DS]Y_G$\%4EEG#U++<TP^8U<=*A5="EF4\7@Z&$RV
MA#$5*/U_%/&XKFP]+$1P-+%SK4(R_A_A+Z$'CKFG&6%R;B'ABGPSD%+,,/'-
M.*\1FN48S+:674<32EB<1E$<#F-?%YQBZV'I5(Y?AUE^"<L16P]7&2P5.EB.
M3WG_ (*'>&/$6L_L.?&?1K%GU+4M%\*:%J^L-'$8QJ&F^%=:T74?$M_.H?;%
M:6]AI]WK]TSEXX+*RGF8,(@#_'4T P,PL#@JW.&+,2?F'8YSC& >0.!7^@A<
M6EK(CQRVT4T4@>-XY%#QR1R*RRI*C*RR12(6CDCD#))&65OE9EK^8_\ X*'?
M\$[O!GP$N]'^*?PCN[BS^'OC#Q)-H>I> KL-./ NMWEK?:MI9\-ZB&$EQX0O
MH+#4+&+2-1C>_P##MU!I]O::CJ.EZBEKHG\6>#WBG2X0P>89'F,G0HX[,'FM
M#%TXRC26(J8>&'Q-&MRV]G%*E3G0ERV2;I-I.,#^I/IY_1]XMXS61>)_!RIY
MC1X6X>AP]Q'E%7%N&.P^6T<SC6RS-\![9>SQD83S%X/-</'DQ2_V7,*4<3".
M(IT/Q>CMQO3"-]] IW %=C*68D9&T#DL>!CD'G/]GG_!.'P[K?A?]C+X!Z;K
M\4MM=W/A.]UVTM98_+-OH_B/7M6U[0T4%58Q3Z3J-IJ$.Y01%?1C   'XV_\
M$[_^"=_@SXY2:E\7/B[//J/@#PIXH@\/Z3X MB(X_&FM:?!9:EJDOBR\99)8
M_"5DM]8V;:+8>5<>(;A[Y-0O[/2[%K'6OZ;K>".'[B*IVX^4;0%4_*JKG"HH
M.%0#:B@*O %+Q@\4*/&>#R_(\%[2MAL%CI9EB,54BU%XA86>%HTL/SOF:C3K
MUG7J123?LZ:<K24>CZ!/@!Q9P)/._%/BUT<!#B?(J.2\,932KRJ8JOEDLT^N
MXS.LRIQA3CAJ=>KEV'P^4X/$<^*=+ZSF%:E@XUL/0J_&G[:O[:?@7]C?X>Z7
MXD\0Z7-XK\9>+KZ]T[X?> ;74XM'G\3WFE0V]SK-[?ZN;35&T3PUH$=_I8UO
M6%TO4Y89]6TO3[;3[J\U*W0?S]7_ /P6(_;&U+Q!+JMC>_#30=,\Y'3P[9>
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FJ=!UY/$8BOBZZA.D3FIRG)4Z=--KW:<%%).[MIJTGM=Z=%V__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 5$# 2(  A$! Q$!_\0
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MV3R7!!O)\&3!R% Z+FNDHHH **** "BBB@#D/$O@F+6;@WEO,(+D_?R,J_\
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>meds-20250304.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaaFibP9z5Z82ekhvWB4bbkKzyUl9LcQkytyb3rmwTwC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:MEDS="http://trxade.com/20250304" elementFormDefault="qualified" targetNamespace="http://trxade.com/20250304">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://trxade.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="meds-20250304_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="meds-20250304_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>meds-20250304_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>meds-20250304_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://trxade.com/role/Cover" xlink:href="meds-20250304.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://trxade.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45236461861728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SCIENTURE
HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001382574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3673928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6308
Benjamin Rd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tampa<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">468-6535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value
    $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCNX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &J+:EJK7AR-[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &J+
M:EJ97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ :HMJ6MT:X9]N!   )!$  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &J+
M:EJ?H!OPL0(  .(,   -              "  ;(,  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ :HMJ6I>*NQS     $P(   L              ( !C@\
M %]R96QS+RYR96QS4$L! A0#%     @ :HMJ6JK$(A8S 0  (@(   \
M         ( !=Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &J+:EHD
M'INBK0   /@!   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( &J+:EIED'F2&0$  ,\#   3
M      "  ;P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(
'  84      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trxade.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>meds-20250304.xsd</File>
    <File>meds-20250304_lab.xml</File>
    <File>meds-20250304_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "MEDS",
   "nsuri": "http://trxade.com/20250304",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "meds-20250304.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "meds-20250304_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meds-20250304_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://trxade.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://trxade.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-25-009737-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-009737-xbrl.zip
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M^'3C^@JL ESE!2PLNK@Z(S>!4FADX=<ENA WT4)7!N$4"_A+ 3]?9HO8QW:
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M] ,C1)#K=F@9>5X)97I77CO+*K!]\A(-H-HL$;_ SK[*JKIQE'-"XH# %S*
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M1+RWM/C> >[LY"^O:K>PQ.DN"A4?CX6*VUJH^'@L5/SZ"Q7O+@*UB:V?QJC
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MXS7,?$[N<45MKX5G:\\B;L[$8DL@M@SQ9V532:-7ZB)ML+X31IF&UKCFF2+
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M+]HK YOKFRETM$HM:/W%$^=L4\[(4<]6/GQPTQ<O-3/HY#,?=%/Y=F[A<0P
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MHEQ6/@BEJH+H)N,V"DYF$G>/IA0>ZA?U^R*V8W'B/EJ)\7HJ"Y+;(S03A]/
M7(R(S(E$5^5#N7]E1C+LWE+TN:Q65^"Z6!0X;*)/NAT"P%ED,=0TL"!\IM.\
MH>R@R4%-DKHK)$'$+I706IFT'3[Z[9O]"6=3B;*M015B<E]".?U<WJ76*26B
MKOG+.5N;;SL'KE%33:X=/*DNFPE![M%+HC06RXJF)$.)E0H2#"W;(C!'!7&>
M8NDTSNS6*3[Z,A=!C<'4WQNWZF\Q_<^_'@_Z+.)!-Q4/^BSB05=N_0TZQ2L
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M/L-1_)(-R6<L[$7YCIJ^,=C EAIAI*J^[A/Q#U&6GJR!+28ZI#8_&^/[INK
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MGN_IN+?;ZZBC[7Y'G4*!<17QC^$,5SL*WG%/>=DO/#%F:6\).<&E,"#YX%Z
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MP3AR&2TJ4#2%DE^G54*;@.@L%RE?P<<*/AX!?/R+D.*SSBB*LR2Y(KITFIE
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MT:Z^'1_+*:763%( $OOQ/8BP;-2+K=N![,J U:MU/0B\;%)U8?1=%G1OH@^
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M;'IO>H(GFDJI<!6B",^A,AEUI; HS  0^_HZLI)#Y$KJ> ]+'<*T>'1*W<1
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MK ?.ROE!O]%H6^.SS?7_]/?W/M6/9/_=.TV1I:YGC_'/03!T=OX?4$L#!!0
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MM6>O,?=^LQ6ZAR&*5Z]NAJ1I26(N/RNUC04,FU8 OK2S;O[491?T$&40$^'
MZL4]VGY3:>!, @LOIY*[&K0(#T$HHB=Y;?^3U(DR]+NU,,C$D19R_F'E%+NG
M5JXI0/]CR3VCGZ^UX6SNE7[>WKV&+I<+A5ANA0_=G\G-W^->+'6 8I[LC&<;
MDUTJVY5282[]5::G)+%Z Z<ED?'.2&+/+;XKOMP'-P<S0A?'!MWS-3@8="?'
M :ID9CD[A?5OQU_D$,N<E,1&.WTE'"-A1,NV[F.EM#^=/S'C9WG6$'@\8DHL
M3AF$=4KV<%XW5E_]XQJ1X9,FF#\"YX8]8PKRP7>-0,-)U/3Q-U!+ P04
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M\<K88M!8&-<403 "VH*6Q?7?"O"3.V^[HDET13F&K[(T-(XSYK7M&<GR#H*
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MW*08  !S?@  "@              @ &KFP  97@Y.2TQ+FAT;5!+ 0(4 Q0
M   ( &J+:EK)MZQ&1R$  (#:   +              "  7>T  !F;W)M."UK
M+FAT;5!+ 0(4 Q0    ( &J+:EK,HOYE)@,  -T+   1              "
M >?5  !M961S+3(P,C4P,S T+GAS9%!+ 0(4 Q0    ( &J+:EHAR\EF_@H
M ("&   5              "  3S9  !M961S+3(P,C4P,S T7VQA8BYX;6Q0
M2P$"% ,4    " !JBVI:+A$^LE8'  #15P  %0              @ %MY
K;65D<RTR,#(U,#,P-%]P<F4N>&UL4$L%!@     &  8 ;0$  /;K      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meds-20250304.xsd" xlink:type="simple"/>
    <context id="AsOf2025-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
        </entity>
        <period>
            <startDate>2025-03-04</startDate>
            <endDate>2025-03-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-03-04" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-03-04" id="Fact000004">0001382574</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-03-04" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-03-04" id="Fact000010">2025-03-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-03-04" id="Fact000011">SCIENTURE HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-03-04" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-03-04" id="Fact000013">001-39199</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-03-04" id="Fact000014">46-3673928</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-03-04" id="Fact000015">6308 Benjamin Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-03-04" id="Fact000016">Suite 708</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-03-04" id="Fact000017">Tampa</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-03-04" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-03-04" id="Fact000019">33634</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-03-04" id="Fact000020">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-03-04" id="Fact000021">468-6535</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-03-04" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-03-04" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-03-04" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-03-04" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-03-04" id="Fact000026">Common stock, par value     $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-03-04" id="Fact000027">SCNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-03-04" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-03-04" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
